Louisiana State University

LSU Digital Commons
LSU Doctoral Dissertations

Graduate School

3-19-2018

5-Lipoxygenase (5-LOX)-5-Lipoxygenase Activating Protein
(FLAP)-Nanodisc Complex: A Model for the 5-LOX-FLAP
Interaction
Erin Elizabeth Schexnaydre
Louisiana State University and Agricultural and Mechanical College

Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations
Part of the Biochemistry, Biophysics, and Structural Biology Commons, Cell Biology Commons, and
the Immunity Commons

Recommended Citation
Schexnaydre, Erin Elizabeth, "5-Lipoxygenase (5-LOX)-5-Lipoxygenase Activating Protein (FLAP)-Nanodisc
Complex: A Model for the 5-LOX-FLAP Interaction" (2018). LSU Doctoral Dissertations. 4503.
https://digitalcommons.lsu.edu/gradschool_dissertations/4503

This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It
has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU
Digital Commons. For more information, please contactgradetd@lsu.edu.

5-LIPOXYGENASE (5-LOX)5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP)- NANODISC COMPLEX:
A MODEL FOR THE 5-LOX-FLAP INTERACTION

A Dissertation
Submitted to the Graduate Faculty of the
Louisiana State University and
Agricultural and Mechanical College
in partial fulfillment of the
requirements for the degree of
Doctor of Philosophy
in
The Department of Biological Sciences

by
Erin Elizabeth Schexnaydre
B.S., Louisiana State University, 2012
May 2018

I dedicate this work to my parents,
Donna and Jared Schexnaydre
And to
Donovan McClelland
Whose love and support
Made this work possible.

ii

Preface
This is a representation of my journey as a graduate student that has defined not only the type of
research I desire to pursue but also the type of scientist I plan to exemplify. The journey has not
been without its challenges, however with each victory over a challenge I have gained the
understanding and experience needed to promote my career as a successful scientist.
When I first started graduate school I never imagined I would take on a completely new
technique that was not established at my university, attend courses to learn about it, and organize
and hold a workshop at the university to promote it. It started when I was developing the question
I was going to address as part of graduate research. The question involved investigating the
structure and function of a protein-protein-membrane complex. The interaction between this
membrane-associated protein and transmembrane protein had not been observed in vitro and I
endeavored to take advantage of the Nanodisc technology which allowed analysis of this complex
in a membrane environment. However, the structural analysis appeared to lay outside the scope
of the primary technique of the lab, x-ray crystallography. Obtaining a crystal of this irregular
shaped protein-protein-membrane complex would be quite challenging. After doing some
extensive research, I came across the technique of cryo-electron microscopy (cryo-EM). Singleparticle cryo-EM provided the opportunity of structural analysis of a single particle which not only
did not require crystallization of the particle but kept the particle in a hydrated native-like state. I
was completely overtaken by the possibilities this technique could provide and started
investigating the feasibility of analyzing the complex with cryo-EM. The current research
demonstrated that analysis of complex structures using nanodiscs had been done before but the
size of this complex was near the size limit of this technique. Although this would be a challenge,
it did not make it impossible. With the support of my advisor, I participated in a threedimensional microscopy course where I obtained a complete grasp of what pursuing cryo-EM
would entail. It was an unbelievable experience and I was so captivated by this technique that I
decided to promote it at Louisiana State University by organizing and holding the 3D CryoWorkshop. This provided its own unique experiences for me. I learned how to obtain funding to
support the workshop, bring in speakers that would provide excellent examples of what has been
achieved with cryo-EM, organize and run both theoretical and practical sessions of the workshop
as well as how to organize a committee and delegate work to others. Since then I have applied
both negative stain and cryo-EM to analyzing this protein-protein-membrane complex and have
formed a collaboration at Baylor of School of Medicine to obtain high quality cryo-EM imaging of
this complex. As I developed the methods for reconstituting this complex in vitro and imaging it
with TEM, I gained advice and perspective on what to do to push my project forward by
participating in Three-Dimensional Electron Microscopy Gordon Conferences. It is at this
conference that I was able to network with other people in the field and obtain encouragement
and support of my project. It was with this support that my project kept driving forward.
Although significant progress has been made, the journey still continues as I optimize the cryoEM imaging of my sample. This work could have not been possible without the continuous
support of my advisor, Dr. Marcia Newcomer. I hope that you enjoy what this work has to offer.
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Abstract
Leukotrienes (LT) are lipid mediators of the inflammatory response that play important roles in
diseases such as asthma and atherosclerosis. Leukotriene A4 (LTA4) is synthesized from
arachidonic acid (AA) by 5-lipoxygenase (5-LOX) with the help of 5-lipoxygenase activating
protein (FLAP), a trimeric nuclear transmembrane protein. Exactly how 5-LOX and FLAP interact
is not well understood, however FLAP is essential for the production of leukotrienes in vivo. I used
nanodiscs (NDs), engineered membrane systems, as a tool to study the 5-LOX-FLAP interaction.
FLAP was incorporated into NDs with a phospholipid composition to mimic of the nuclear
membrane. Structural features were observed with single-particle negative stain transmission
electron microscopy (TEM). This is the first in vitro reconstitution of this protein-proteinmembrane interaction.
I demonstrated that a distinct 5-LOX sequence motif (tri-lysine motif) modulates activity and
confers dependence on FLAP. Substitution of motif with a highly conserved sequence found in
homologous enzymes results in ~20-fold higher 5-LOX product levels in stimulated HEK cells
relative to the wild-type-expressing cells. However, despite the fact that the presence of FLAP
increases product levels in wild-type-expressing cells, it significantly reduces the amount of
product detected in cells which express the mutant enzyme. This data suggests that the tri-lysine
motif limits enzyme activity and that this inhibition must be compensated by the presence of FLAP
for effective LT biosynthesis.
5-LOX activity is modulated by natural products. The frankincense derived compound 3-Acetyl11-Keto-beta Boswellic Acid (AKBA) is a well-known inhibitor of 5-LOX. We investigated the
mechanism of inhibition of 5-LOX by AKBA and defined a novel allosteric binding site. In the
presence of FLAP, AKBA effectively blocks the initiation of LT production in HEK cells. Data from
immuno-fluorescence microscopy and in vitro studies suggest that AKBA interferes with the 5LOX:FLAP interaction. Combined, these studies support a specific 5-LOX-FLAP-membrane
interaction and provide a path to define the molecular details of this interaction.

vii

Introduction
The Inflammatory Response as Part of the Innate Immune Response
The innate immune response is the first line of defense against foreign invaders for any organism.
It is responsible for neutralizing the majority of foreign bodies that attempt to enter the human
body. This defense system ranges from physical barriers such as the skin to cellular and chemical
components such as specific immune cells and the chemical mediators they produce(1). The
innate immune response is known for its non-specific nature of action but it can recognize
pathogens with what are called pattern-recognition receptors (PRRs), which include Toll-like
receptors as well as cytoplasmic receptors and they recognize patterns on foreign invaders
called pathogen-associated molecular patterns (PAMPs)(2). A significant part of the innate
immune response is the inflammatory response. It can be initiated as both a response to a
pathogen invasion or a response to injury to healthy tissue or cells(1,3). There are five cardinal
signs of inflammation: rubor (redness), tumor (swelling), calor (heat), dolor (pain) and functio
laesa (loss of function). The redness and heat is due to vasodilation and an increase in blood flow
to the site while swelling is due to the increased vascular permeability. The pain is a consequence
of pressure build-up on nerve endings due to the swelling(4,5). All of these actions raised to an
overwhelming level can cause loss of function.
Calcium has a significant role in the inflammatory response and permits the release of histamine
from mast cells(1). While this process depends on the extracellular concentration of calcium,
other inflammatory pathways create an influx of intracellular calcium which triggers the
production of pro-inflammatory mediators(6,7). There are several cell types that participate in the
inflammatory response. These include white blood cells known as leukocytes, which includes cell
types such as monocytes, neutrophils or macrophages. Other cells include dendritic cells, mast
cells, platelets, and lymphocytes. The main cell recruited to the site of the origin of inflammation
is the neutrophil, otherwise known as polymorphornuclear cells for their multi-lobed nuclei(8).
Neutrophils are the most abundant white blood cell in blood circulation(8). Macrophages are
another cell type that can be commonly found at a site of inflammation though while in the resting
state their numbers are usually low. Macrophages are mainly known for phagocytosis of
pathogens or dead cells and tissue, but they are also involved in wound repair through the
release of anti-inflammatory mediators (3).
The main objective of the inflammatory response is to amplify signals through recognition and
recruitment. It does this through many different types of chemical mediators, one type being lipid
mediators such as leukotrienes (LTs)(1). These mediators are important for enabling the first line
of defense against pathogens and are powerful but short-lived, which is fitting for a response that
has the potential to damage healthy tissue. The production of other pro-inflammatory mediators
called prostaglandins and thromboxanes are inhibited by Ibuprofen or Aspirin, otherwise known
as nonsteroidal anti-inflammatory drugs (NAIDs), which non-selectively inhibit the enzymes
cyclooxygenase-1 and -2 (COX-1/-2)(9). These pro-inflammatory mediators as well as
leukotrienes are derived from an omega-6 fatty acid called arachidonic acid (AA)(10,11). This
polyunsaturated fatty acid (PUFA) is the precursor of inflammatory eicosanoids which include
signaling molecules such as leukotrienes.
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Leukotriene Biosynthesis
Leukotrienes are polyunsaturated lipid mediators of the inflammatory response as part of the
innate immune response. Leukotrienes include LTA4, an unstable epoxide that is the precursor to
LTs, LTB4, as well as LTC4, LTD4 and LTE4, which are known as the cysteinyl-LTs(cysLTs). LTB4 is
synthesized mainly in neutrophils and it is a strong chemoattractant which recruits more
neutrophils to the site of inflammation(6,12). CysLTs on the other hand increase vascular
permeability and vasodilation, which can cause the bronchoconstriction and mucus secretion
exhibited by asthma patients(6,12). These signaling molecules bind specific receptors that
trigger the manifestation of these symptoms. The specific receptors known as BLT and CysLT
receptors are G-protein-coupled receptors for which these molecules bind at nanomolar
concentrations(7,13,14). Excessive release of these mediators triggers over-inflammation which is
detrimental to the surrounding tissue. LTs have been exhibited in diseases such as asthma and
atherosclerosis. In asthma LTs act as strong chemoattractants and cause bronchoconstriction. LTs
have been shown to be released from mast cells during an asthma attack (15). Asthma is
suggested to affect around one sixteenth of the people around the world. The main treatment is
still corticosteroids, which only reduce some of the symptoms of asthma (6). However,
corticosteroids only suppress the effects of the white blood cell, the eosinophil and not
neutrophils; therefore they do not inhibit LT biosynthesis (7). Furthermore, it has been
demonstrated that they cause an increase in the expression of an important protein in LT
biosynthesis called 5-lipoxygenase activating protein (FLAP) (7). The initiator of LT biosynthesis
is in a family of enzymes called lipoxygenases (LOXs) and requires the help of FLAP(16,17).
LOXs are enzymes that contain a non-heme iron and metabolize polyunsaturated fatty acid
substrates. They are not universally expressed in yeast or bacteria, but they are found in animals
as well as plants and fungi(18). There are six isoforms of lipoxygenases in humans. These
isoforms include 5-lipoxygenase(5-LOX), 15-lipoxygenase-1(15-LOX1), 15-lipoxygenase-2(15LOX2), 12/12R-lipoxygenase(12/12R-LOX), and epidermis-type lipoxygenase 3 (eLOX3). All of
the human LOX genes are found in the same region on chromosome 17 except for 5-LOX, which is
located on chromosome 10(19). The 15-LOX1 and 15-LOX2 enzymes have been suggested to play
a role in formation of atherosclerotic plaque formation by having the capacity to oxidize the lipids
that make up low density lipoproteins (LDLs) (20,21). While the 5-LOX enzyme has been shown to
contribute to the bronchoconstriction in asthma, as well as arterial wall inflammation (22).
5-Lipoxygenase (5-LOX)
5-lipoxygenase is the initiator of leukotriene biosynthesis in that it catalyzes the first reaction of
arachidonic acid (AA) to leukotriene (LTA4)(23,24). 5-LOX translocates to the nuclear membrane
upon an increase in intracellular Ca2+ concentration (25,26), along with an enzyme called
phospholipase A2 (PLA2). PLA2 cleaves arachidonic acid (AA) from phospholipids in the nuclear
membrane so that it is then available for 5-LOX to be converted to LTA4. It converts AA to LTA4 in
a two-step reaction that first converts AA to 5- hydroperoxyeicosatetraenoic acid (5-HPETE) by
first a hydrogen abstraction followed by an oxygenation and through an additional hydrogen
abstraction 5-HPETE is converted to LTA4(27,28). Although 5-LOX has the same general fold of
regulatory domain and catalytic domain as other LOXs(29), it has some unique structural features
that have been attributed to its unique phenotypical display. Of the LOXs it is the most structurally
unstable and has a very short half-life (30,31). 5-LOX is known to require a helper protein, FLAP a
nuclear transmembrane protein which binds AA in vivo, to obtain endogenous AA for LT
biosynthesis (32).
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The helper protein FLAP enables 5-LOX to access substrate and promotes completion of the twostep transformation of AA to LTA4 (16,17,33,34).
5-LOX’s expression in macrophages indicates a connection of 5-LOX’s inflammatory mediation to
enhancing atherosclerosis (35). 5-LOX’s role of converting AA into LTs suggest its significance in
the inflammation that promotes the accumulation of atherosclerotic plaques. One study in mice
demonstrated the significance of the 5-LOX gene by comparing 5-LOX expression levels in mice
resistant to atherosclerosis to a strain that did not have resistance (36). The resistant mice
demonstrated a significant reduction in 5-LOX and 5-LOX products compared to non-resistant
mice(36). Furthermore, 5-LOX post-translational modifications have prominent roles in the
function of 5-LOX. While phosphorylation of 5-LOX at Ser-271 by MAP kinases promotes the
activity of 5-LOX to produce LTs (37,38), phosphorylation of Ser-663 may have a different role. A
point mutation that mimicked the phosphorylation of Ser-663 demonstrated reduced LT
production, however, it exhibited lipoxin production, an anti-inflammatory compound normally
produced by the combined activities of 5-LOX and 15-LOX (39). 15-LOX and 5-LOX are normally
expressed in different cells. The LTA4 produced in neutrophils is transferred to platelet cells to be
picked up by 15-LOX/12-LOX to produce lipoxins (40). Phosphorylation of 5-LOX at Ser-663 may
present a way to by-pass this mechanism. Many factors in 5-LOX’s regulation play a role in
contributing to atherosclerosis. One study found that 5-LOX gene promoter variations enhanced
the development of atherosclerosis in carotid arteries (41). Overall, links between inflammation
and atherosclerosis have been established, which suggests that 5-LOX and FLAP have a crucial
role in atherosclerosis susceptibility.
Like other LOXs, 5-LOX contains a small regulatory domain and large catalytic domain (42) The
regulatory domain binds Ca2+ which triggers 5-LOX to translocate to the nuclear membrane upon
an influx of Ca2+ in the cell (43-45). The catalytic domain holds the non-heme iron coordinated by
three histidine residues as well as the main-chain carboxyl of the C-terminal residue, isoleucine
(42).
One unique 5-LOX feature is in ahelix2. Where other LOXs have six to seven turns in this helix, 5LOX has only three (42). Additionally, this helix is bent ~45° from other LOXs’ ahelix2 (42). The
result of this is that two residues (F177 and Y181) point down towards the active site blocking
substrate access(46). These residues have been shown to be important for product specificity by
allowing correctly orientated substrate entrance into the active site(46). It is suggested that unlike
other LOXs that AA enters carboxyl end first in order for the pentadiene attack to take place at the
right carbon of AA(29).
Another unique structural feature is a triple lysine motif located at the C-terminus of the enzyme
just 20 amino acids upstream of the carboxyl end that makes up the catalytic center of 5-LOX. In
this motif, KKK663-665, the lysine-665 is a leucine, in all other LOXs the substitution of the Leucine
would break salt links and pi-cation interactions observed in other LOXs(42). The mutation of this
triple lysine motif to ENL, in a form of 5-LOX that lacks membrane binding loops and two
cysteines, increases the melting point and prolongs the half-life of this variant allowing
crystallization and structural determination of the 5-LOX enzyme(42). This motif was suggested to
be an auto-inactivation mechanism and therefore a key regulator of 5-LOX activity. In my work
investigating this motif, a more intricate intrinsic regulation by this motif was revealed: it confers
5-LOX’s dependence on the helper protein, FLAP.
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5-Lipoxygenase Activating Protein (FLAP)
In contrast to other members of the LOX family, 5-LOX requires a nuclear transmembrane helper
protein (FLAP) in order to effectively transform its substrate AA (33). Upon Ca2+ stimulation 5-LOX
co-localizes with FLAP at the nuclear membrane and several studies argue strongly for an
interaction between the two proteins (47-49). The structure of FLAP with an inhibitor-bound was
solved to 4.0Å(34). Trimeric FLAP is made up of three monomers and the trimer crosses the
nuclear membrane at 60Å length and 30Å width with its cytosolic loops and luminal helices(34).
The inhibitor binding sites in FLAP reside in the plane of the membrane between monomers of
the protein(33,34). These sites give a hint as to where AA could be held by FLAP.
FLAP is a member of the membrane-associated proteins in eicosanoid and glutathione
metabolism (MAPEG) superfamily. Another member of the MAPEG family is invovled in LT
biosynthesis. This enzyme is leukotriene C4 synthase (LTC4S), which is also a nuclear
transmembrane protein. It catalyzes the coversion of LTA4 to LTC4 in conjunction with
gulathione(GSH)(50). Unlike all other members of the MAPEG family, FLAP does not bind GSH
nor does it have any known activity, which puts it in a subclass of its own(51,52).
The effects of overproduction of 5-LOX-generated lipid mediators are exhibited in pathologies
such as asthma and atherosclerosis and it is known that 5-LOX depends on FLAP for LT
biosynthesis. However, little is known about how FLAP hands off substrate to 5-LOX and the
interaction between the two has been strongly suggested but not structurally observed. 5-LOX’s
unique dependence on a helper protein makes the study of the 5-LOX-FLAP interaction of great
interest as a possible drug target for a member of a group of enzymes that have the same overall
fold and catalytic centers, and bind the same substrate.
5-LOX-FLAP Interaction
An interaction between 5-LOX and FLAP has been strongly suggested but has never been
observed. With immuno-fluoresence microscopy it has been demonstrated that 5-LOX and FLAP
colocalize at the nuclear membrane in HEK293 cells. Although fluoresence micrscopy put 5-LOX
and FLAP in close proximity to each other it was with a study by Gerstmeier et al that used
proximity ligation assays to determine that 5-LOX and FLAP were within a 40nm distance of each
other(49). Additionally, they demonstrated that in HEK cells FLAP rescued 5-LOX mutants’
function with impaired nuclear locatlization and activity (49). One example depicting the
importance of investigating the interaction between 5-LOX and FLAP is a study done in mice with
atherosclerosis that demonstrated that the FLAP inhibitor MK-886 lead to a decrease in plaque
formation(33).
In my thesis work I have demonstrated the first in vitro reconstitution of the 5-LOX-FLAP
interaction. This was made possible through the use of engineered membrane systems called
nanodiscs (NDs). NDs are small scale bilayers that are held together by two amphipathic
membrane scaffolding proteins (MSP)(53-55). Bacterial overexpression and purification of 5-LOX
and FLAP, His and Strep tagged, respectively, were applied in the reconstitution. By
incorporating FLAP into nanodiscs, the ND supported a native-like environment for 5-LOX and
FLAP to interact. Additionally, the nanodiscs were constructed with lipids that mimic those found
in the nuclear membrane.
The purpose of my study of the interaction between 5-LOX-FLAP is to define a model for this
interaction in the presence of a bilayer, which is supported by the generation of LTs. The
4

generation of LTs by this in vitro protein-protein-membrane complex sheds light on the function
of the membrane in initiating reaction of LT biosynthesis. Additionally, product analysis of this
complex allows us to investigate how FLAP holds the intermediate product (5-HPETE) in the active
site so that 5-LOX completes the two-step reaction. The technique I have chosen to use to evaluate
the 5-LOX-FLAP interaction and to observe just how FLAP interacts with 5-LOX is single-particle
cryo-electron microscopy (cryo-EM). The individual crystal-structures of FLAP and 5-LOX enable
the cryo-EM analysis of the complex to be even more powerful. Since the interactions between 5LOX and FLAP and the interactions of each with the bilayer could be subtle, it makes the complex
a subject for cryo-EM analysis. The cryo-EM complex data and the x-ray crystallography data of
each protein provides a chance to hypothesize about the function and regulation of LT
biosynthesis in diseases. Moreover, knowledge of the 5-LOX-FLAP-membrane interaction can
help in the development of new ideas into analysis of this unique drug target.
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I. Single-Particle Cryo-Electron Microscopy
Single-Particle cryo-electron microscopy (Cryo-EM) is a structural biology technique used to
analyze the three-dimensional structure of in vitro single particles such as proteins, protein
complexes, protein-rRNA molecules like the ribosome(56-58), as well as helical structures such as
chromatin fibers(59) and DNA-protein complexes(60). These particles are imaged in a frozen
hydrated environment which keeps them in a more native-like state. Traditional EM uses heavy
negative stains such as uranyl acetate or uranyl formate, which add contrast to the sample, but at
the same time dehydrate the sample and can cause an altered three-dimensional structure of the
particle. In this frozen hydrated state, the particles are ideally in different orientations. The
images taken from the EM (micrographs) contain two-dimensional particles that can be picked
out and placed into classes based on their orientation as demonstrated by the single particle of
the alcohol oxidase (AOX) enzyme (61)(Figure. 1). These two-dimensional classes are then

Figure 1. Cryo-EM
micrograph(a) and 2D
averages (b) of Alcohol
Oxidase from Pichia
pastoris. Source: (61).
independently averaged and these averages are then used to reconstruct a three-dimensional
representation of the particle. Cryo-EM, unlike the traditional method of obtaining
macromolecular structures by x-ray-crystallography, is analyzed directly by imaging instead of
analysis of a diffraction pattern from a crystal. However, each technique aims to obtain a threedimensional representation of a molecular particle of interest.
In order to comprehend the applications of x-ray crystallography and cryo-EM in today’s
structural biology field, we must start from the beginning. However, let’s first define x-ray
6

crystallography and cryo-EM. Both techniques allow a researcher to reconstruct a threedimensional representation of a molecule such as a protein or a complex of proteins. For x-ray
crystallography, a researcher must identify the ideal conditions that will crystalize his or her
protein. This crystal contains identical repeating units made up of the protein and therefore locks
the protein in one conformation while also amplifying the information that will be extracted from
the crystal (Figure. 2). Once the protein is crystalized it is hit with a beam of x-rays usually
supplied by a synchrotron facility. These x-rays scatter off the crystal in a pattern that is
representative of the molecule making up that crystal. Computational approaches then take the

Figure 2. Protein crystal. Source:
Biomolecular
Crystallography
by
Bernhard Rupp, © 2009-2014 Garland
Science/Taylor & Francis LLC.
diffraction pattern created by the scattered x-rays and calculate a three-dimensional electron
density map from which a molecular model is constructed and made consistent with the density
map. In contrast, cryo-TEM is able to image proteins or complexes of proteins in a frozen state
using electrons in a similar way light in used in a light microscope. Each image of a protein or a
complex of proteins is termed a single-particle, however, unlike in x-ray crystallography these
particles can be in a variety of orientations and conformations. These different conformations are
separated into groups where several particle images of each group are averaged together to
obtain structural details. These two-dimensional images from several different viewpoints are
then computationally reconstructed into a three-dimensional structure as seen for the
Methonococcus maripaludis chaperonin (Mm-cpn)(Figure. 3)(62).
Although electron microscopy in today’s structural biology field of single-particle threedimensional reconstruction is considered a “naïve technique” compared to x-ray
crystallography, the origins of each developed around the same time. Röntgen first discovered X-

Figure
3.
Single-particle
Cryo-TEM
reconstruction of Methonococcus maripaludis
chaperonin(Mm-cpn) Left. 2D class averages
with corresponding 3D representations Right.
3D reconstructions. Source: (62).
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rays in 1895 and J.J. Thomson discovered electrons in 1897. As we begin to learn more about
these two, we see that they share the property of acting as both a particle and a wave, which is the
same way light functions. To understand this link and how is applied in future explorations of
science we must go back even further to the first applications of light that enabled us to see the
unseen.
The Nimrud lens was the first step taken to see beyond what could be seen by the naked eye.
Around 710 BC this lens, which was comprised of crystal rock, was used as a magnifying glass.
The invention of the first microscopes in 16th century and their development throughout the 17th
century lead to monumental discoveries such as the first observations of cells. While microscopes
were developing so were scientists’ understanding of crystals. It started in 1611 with the German
mathematician, Johannes Kepler’s analysis of the six-cornered snowflake, which lead to Xliels
Stensen’s Law of the Constancy of Interfacial Angles in 1670. In 1784 came Abbé Haüy’s Laws of
symmetry, rational intercepts, and of constancy of crystalline form. Then in 1830 German
physician, John Fredrich Christen Hessel concluded that morphological forms come together to
give exactly thirty-two kinds of crystal symmetry. This was followed by the 1848 discovery of
fourteen unique lattices (Bravais lattices) and 230 possible space groups in 1891.
With Louis de Brogile’s discovery of the particle and wave functions of an electron and Hans
Busch’s discovery that a magnetic lens could direct electrons, Ernst Ruska and Max Knoll applied

Figure 4: First electron
microscope designed in
1932. Source: Electron
Microscope Deutsches
Museum- Flicker.com
light optics theory to electrons by designing the first electron microscope (Figure. 4). At around
the same time Bragg’s particle and Barkla’s wave function discovery of x-rays, as well as the
development of the understanding of the nature of crystals, lead to Max von Laue’s invention of
using crystals as diffraction grating for x-rays and to the first x-ray crystal structure, which was of
salt (NaCl), the very thing today’s protein x-ray crystallographers do not want to see in their
crystal’s diffraction pattern.
Both techniques aim to see structural details at the molecular level but each takes different paths
to get there. EM was first able to capture images of organelles in a section of a cell and then with
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improvements to the microscope and to sample preparation one is able to obtain high enough
resolution images in order to reconstruct three-dimensional models of macromolecules (See
Timeline). X-ray crystallography started with application to small structures, then more complex
chemical structures and then finally DNA and proteins (See Timeline). These two techniques have
been around for relatively the same amount of time, however EM initially examined larger
biological structures on the cellular level (smaller when compared to achievements of light
microscopes) and then pushed the limit to obtain single-particle images. X-ray crystallography
was first applied by analyzing crystals of salt and then to analyzing crystal structures of proteins.
X-ray crystallography was driven by chemistry and cryo-EM was driven by biology, while both
have roots in physics.

TIMELINE: Microscopy and X-Ray Crystallography through Time. First Intact Cell TEM Image(63);
3DTEM Tail of bacteriophage T4 (64); 3D Cryo-EM of Bacteriophage T4 (65)
Since the take-off of these techniques, both have evolved to answer the complex biological
questions posed by researchers today. In the same way that people across the world can be so
different but fundamentally the same, so are the techniques of cryo-EM and x-ray
crystallography. People learn different approaches to living life the same way these techniques
have developed to address scientific structural questions. For example, the stereotypical French
9

person is known to be laid back while stereotypical Germans are known for their strong work
ethic. Neither person has a better approach to living life than the other, however both have their
advantages and disadvantages. In turn, these different approaches each highlight distinctive
aspects of human life. In the same way, cryo-EM and x-ray crystallography approach structural
biological questions in different ways, therefore, allowing a researcher to choose the best
technique suited to address his or her structural question. This choice is dependent on the
advantages and disadvantages of each technique as well as the nature of the question being
posed by the researcher. X-ray crystallography is better suited for small molecules that are easy
to crystallize, while cryo-TEM is better suited for larger molecules or complexes of molecules that
can be detected by a TEM. Additionally, x-ray crystallography is capable of giving a researcher
high-resolution structural detail while cryo-EM’s vitrified hydrated samples allow a researcher to
observe native-like information from his or her sample. The overlap between these two
techniques has increased with the rapidly evolving advancements in cryo-EM. These
advancements span from the microscope body itself to the imaging cameras and even to the
computational three-dimensional reconstruction software. For many scientists, including myself, it
is not a question of either, but taking advantage of both techniques to obtain both detailed
structural information as well as overall biological information. It is like looking at the earth from
outer space, but instead of just seeing the different continents you also see the exact locations
where communities of people have settled to live. Both of these perspectives are needed to make
conclusions about human life on earth. Therefore, it is the complementary aspect of these
techniques that allows information to come together to create a biological story.
In my graduate work with cryo-EM I have analyzed the single particle of a protein complex (5LOX-FLAP) in a membrane environment. Next, I will take you through the process of prepping a
single-particle biological sample for imaging in the microscope to analyzing the micrographs for
the single-particles and three-dimensional reconstruction of the particle.
Sample Preparation
Negative Stain Preparation
Once a complex is reconstituted it is first analyzed by negative stain EM to observe the
homogeneity of the sample and successful interaction of the components. Negative stain analysis
samples are applied to a 300 mesh Formvar and carbon coated copper grid (Figure. 5) after it had

Figure 5. 300 mesh FCF copper
grid. Source: EM Solutions
been glow discharged for 30 seconds using a 12mA current. The thin carbon film is normally
hydrophobic and glow discharging the grids makes them hydrophilic. When the grid is glow
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discharged it is put in a chamber with a partial vacuum where the air inside the chamber is
ionized when an electron potential is created by a high voltage that is applied between a cathode
and an anode. The negatively charged ions are deposited onto the carbon film making it
temporarily hydrophilic(66). During glow discharge the ionized gas in the chamber forms a
plasma which is seen as a purple glow (Figure. 6). When a sample is applied to a grid that is not
glow discharged it will bead up on the grid and the sample will not be optimally deposited on the
grid, but when glow discharged the sample spreads out on the grid.
Before imaging the grid a heavy metal negative stain must be applied in order to add contrast to
the sample. In electron microscopy, exposure of a sample to a high energy electron beam
impacts the sample and energy is absorbed by the sample. Biological samples, made principally
of carbon, oxygen, nitrogen, and hydrogen, are not very electron dense and therefore do not

Figure 6. Leica EM ACE 600
plasma glow from glowdischarging
absorb this energy well. Negative stain adds the density needed to provide contrast to the
sample. After negative staining, the grids can be directly imaged in the microscope; however, a
more intricate process is needed for cryo sample preparation. Single particle negative stain
imaging is predominately used for preliminary imaging for homogeneity of the particle as well as
uniform complex formation. However, negative stain has been used to analyze single particles for
structural details as done in a study by Burgess et al. that examined the structures of the motor
proteins, myosin and dynein and aligned and averaged negative stain particles for twodimensional details (67). Other work such as that done with anthrax toxin pore achieved a threedimensional structure of a negative stained particle(68) which was also solved with cryo-EM(69).
Cryo-Plunge Freezing
For single-particle samples that will be prepared for cryo-EM imaging you would use what are
called Holey grids. In these grids each square contains rows of empty holes surrounded by a
carbon support film. The grids are glow discharged the same as the carbon coated copper grids.
The grid is held by a special pair of forceps that attach into a cryo-plunge apparatus. The
chamber containing the grid has a humidity control so that when the sample is applied it
minimizes the evaporation rate of water from the grid, which would otherwise concentrate the
sample. The sample is applied and mechanically blotted for a preset number of seconds before
being plunged in to liquid ethane where it is instantaneously frozen. This liquid ethane is
prepared by cooling ethane gas with liquid nitrogen so that it state transitions to a liquid. The
melting temperature of liquid ethane is -182 ºC and it is used over liquid nitrogen (melting
temperature: - 209 ºC ) because of its higher heat capacity which allows the sample to be frozen
more rapidly (70). When the sample is blotted on the grid a thin layer of the sample fills the holes.
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Subsequently, when the grid is plunge frozen into the liquid ethane the thin layer of liquid sample
becomes a thin layer of vitrified sample, meaning that the sample was frozen so fast that it does

Figure 7. Vitrification of cryo sample in
liquid ethane. Source: Gabriel Lander
not allow the formation of ice crystals (Figure. 7). This allows for optimal imaging of the imbedded
particle because ice crystals damage the particle and would disrupt imaging and they can be
seen very well in the microscope. Once the sample on the grid is frozen in liquid ethane it must
be transferred to liquid nitrogen and placed in a small grid storage box. This step is one of the
critical points where the grid can be subject to what is called ice contamination, meaning
moisture from the air crystalizes on the grid and thus potentially ruins the sample.
From here the grid storage box must be transferred to a liquid nitrogen storage container until it
is ready to be imaged in the microscope.
Imaging
The Transmission Electron Microscope (TEM)
An electron microscope is composed of an electron source, electromagnetic lenses, a specimen
holder, and detectors, as well as additional components such as an energy filter and phase plate

Figure 8. JEOL 1400 TEM Source: EM Core Facility at the University
of Missouri-Columbia.
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(Figure. 8). The electron source is made up of a filament such as tungsten or lanthanum
hexaboride (LaB6) or a field emission gun (FEG). Tungsten and LaB6 are thermal filaments,
meaning heat is applied to the filament which causes the emission of electrons. The FEG applies a
strong electrical field near the filament which causes electrons to tunnel out of the filament. FEG
supplies a steadier and more power beam than the tungsten and LaB6 filaments and is commonly
found in high resolution cryo-TEMs. Electromagnetic lenses are coils of copper wire inside iron
pole pieces and the current through the coils creates a magnetic field. There are several
electromagnetic lenses within the microscope which include a condenser lens, an objective lens,
an intermediate lens, and a projector lens. The specimen holder is partially immersed in the bore
of the objective lens due to the small focal length of the lens. Detectors consist of a fluorescent
screen where a specimen can be viewed directly, as well as cameras which can be either
charged coupled devices (CCDs), which indirectly detects electrons, or direct detection devices
(DDDs), which directly detect electrons.
In negative stain imaging the prepared grid can be directly placed into a specimen holder that
inserts into the microscope. The microscope is under a vacuum so the specimen holder is first
inserted into a specimen chamber, pumped to the vacuum of the microscope before hand and
then fully inserted such that the specimen lies in a small space between the condenser lens and
objective aperture lens. In order to start imaging, the high voltage that supplies the electron
beam needs to be turned on. Once the sample is inserted, the beam is turned on and the grid can
be immediately visualized on a fluorescent screen where initial focusing takes place. Once initial
focusing is done on the fluorescent screen, finer focusing of the sample is done using a camera.
This can be in the form of a CCD camera or DDD camera. For high resolution imaging of particles,
a direct detector is optimal.
In order to understand why direct electron detectors are an innovation in single-particle cryo-EM,
we must first look back at how electron micrograph image detection has evolved over time. The
first form of detection of electron micrographs for TEM was halide emulsion film. The electrons
from the TEM would hit the halide and convert it into silver, which could be developed with
various chemicals to extract an image. EM films have a wide field of view, high contrast and give
a high signal to noise ratio, which is described as the detective quantum efficiency (DQE).
However, film requires a long exposure time and it is a tedious process developing the film.
Nevertheless, it is interesting to note that the first TEM 3D structure was reconstructed with film
micrographs (64). A major breakthrough came with the ability to use digital cameras for EM. This
camera is the CCD camera, which uses a scintillator to detect electrons and convert them to a
photon signal through a fiber optic network and then back into an electrical signal to be viewed
by imaging software (Figure. 9). Not only was it easier to acquire images, but also CCDs do not

Figure 9. CCD camera detection (left) versus DDD camera (right) detection
Source: 3D Microscopy Course-Winter school at the University of Zurich
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require a long exposure time. However, the resolution as described by the modulation transfer
function (MTF) can be lower than film when collecting high quality micrographs for 3D
reconstruction. The MTF evaluates the difference in the input and the output signal in terms of
spatial frequency. The MTF of a CCD camera is dependent on the pixel size and the quality of the
fiber optics. Since the electrons initially detected are converted into photons and then back into
electrons, information can be lost in the process. When comparing imaging of amorphous carbon
film with both a CCD camera and film, it was found that CCD cameras were better at detecting
low resolution data while film was better at detecting high resolution data(71). What was needed
was a camera that could be used to collect high-resolution data in a short exposure time.
This camera is the direct electron detection camera, which as its name states directly detects
electrons therefore eliminating the conversion process. Direct electron detectors are based on
Monolithic Active Pixel Sensor (MAPS) technology (72) and designed by the Complementary
Metal-Oxide Semiconductor (CMOS) method. Direct electron detectors are composed of pixel
transistors and photodiodes on top a p-epitaxial layer (73). When electrons hit this sensor the
electrons generate more electrons by ionization, with each electron producing several ionization
electrons. The electrons are collected by each pixel and put into a digital format. These direct
detectors read out data at a much higher frame per second (fps) rate than CCD cameras. The
UltraScan 4000 indirect detector reads at 0.2 fps with a 15μm pixel size while the DUOS
integrating direct detector has a 20μm pixel size functioning at 30fps, however it has a smaller full
frame readout (74). The K2 Summit in counting mode has a 5μm pixel size and runs at 400fps with
a 3X larger full frame than the DUOS and 7X larger full fame when functioning in super-resolution
counting mode (74). The differences in the K2 Summit’s different modes of detection are featured

Figure 10. Direct electron detection. Source: 3D Microscopy Course-Winter school at the
University of Zurich
in Figure 10. The advancement of direct electron detectors has been fueled by the drive to push
the resolution limit of structural reconstruction of macromolecules with cryo-EM. The year 2015
was a flourishing year for cryo-EM with over 100 molecular structures solved with the technique
(75). The advancement of direct electron detectors has significantly contributed to this success
and has allowed cryo-EM to become a competitor to x-ray crystallography.
Unlike with negative stain imaging, cryo sample grids must be kept at liquid nitrogen
temperatures during transfer to the microscope, as well as while imaging. Before imaging cryo
samples, the microscope must be cooled down with liquid nitrogen, then the grids stored in
liquid nitrogen must be seated into a cryo specimen holder (Figure. 11), which has a mini dewar
attached, and vacuum must be applied the day before. This is another critical step that is prone to
ice contamination. The mini dewar keeps the sample cold while in the microscope. Once placed
in the microscope the grids are imaged under a low electron dose. This dose ranges from 10-20
e-/Å2 while in traditional negative imaging it can be up to 50-100 electrons/pixel(67,76). One area
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on the grid is sacrificed as the focusing area, meaning that the sample there is too damaged due
to the time the beam has impacted the area as well as the slightly higher electron dose used in
focusing. Using what is called a minimal dose system (MDS), the microscope switches to another
hole for acquisition once the sample is in the optimal focus(77). When the cryo sample is
completely in focus you will not see the particles because they do not have contrast. In order to
gain contrast, the sample must be slightly defocused typically around 0.5-3.0µm at the cost of
resolution in the process (78). From here micrographs can be taken for analysis and 100s to 1000s
of micrographs can be taken and single particles analyzed.

Figure 11. Gatan Cryo-holder
There are a few components to an electron microscope that can potentially help the quality of the
micrographs. High resolution cryo-EM are usually 300kV microscopes, meaning that they have a
higher operating voltage over the 120 and 200kV microscopes. One accessory is an energy filter
which is a component that uses electron energy loss spectrometry (EELS). It works by evaluating
the energy distribution of electrons and removing the electrons that were inelastically scattered
from the sample(79). This filtering process helps reduce background noise and also improves
image amplitude contrast(79,80). Another component is a phase plate to give phase contrast
when imaging. This is normally obtained by defocusing, which is good for getting high spatial
frequency information but low partial frequency information. However, phase plates allow for a
large range of spatial frequency information(81). A phase plate is placed after the objective lens
in the diffraction plane and acts by changing the normally sine curve seen in the contrast transfer
function (CTF) to a cosine curve(82). The CTF is a mathematical representation of much of the
phase contrast of the sample is transferred to the observed image in terms of spatial frequency.
The CTF is best described by Joachim Frank as “The description of the relationship between
observed image contrast and projected object potential, and the way this relationship is
influenced by electron optical parameters, is the subject of the contrast transfer theory”(83).
There are two main different types of phase plates, the Zernike phase plate (ZPP) and the Volta
phase plate (VPP). The ZPP is made up of amorphous carbon with a hole in the center and was the
standard phase plate for a time but it had a short lifespan, however VPP is continuous carbon and
can be used for years. However, because the beam passes through a carbon film some signal is
lost due to the scattering of electrons and it can also introduce some astigmatism due to the
uneven surface of the carbon film(81).
Analysis
Once micrographs of a particle are collected they are ready to be analyzed computationally for
three-dimensional reconstruction. There are several single-particle reconstruction software
packages available and the major ones EMAN2, RELION, and SPIDER. All of these programs
perform the same basic steps but the way they go about it can be slightly different. EMAN2 is
good at 2D class averaging but RELION is preferred for constructing a 3D initial model. For a
given particle one may choose to do some steps in one program and perform the rest on another.
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Data can be carried over during some steps from one program to another program and continued
to be processed as long as the data files are in the correct format.
These three software programs are open source and are accompanied with online tutorials so
they are commonly used and updated by the developers as well as easy to excess.
The first version of EMAN2 was released in 1999 and updated versions are released at least two
times a year. EMAN2 has a C++ core library and uses Python scripting language with command
lines and GUI displays for image visualization and manipulation(84). Over the years threedimensional reconstruction programs have become more user friendly, though some
understanding of the Linux environment is still required.
Single-particle cryo-EM has come a long way over the past several decades and its foundation
recently celebrated with the 2017 Noble Prize in Chemistry for single-particle cryo-EM by
Richard Henderson, Joachim Frank, and Jacques Dubochet. The evolution of the attainable
resolution of some protein structures has come a long way in cryo-EM. For example, GroEL
chaperonin complexes, a 10-12 subunit complex with 57kDa monomers, were first negatively
stained in 1979 and viewed just as single-particle images(85) and later a low resolution threedimensional structure at 11.5Å was produced in 2001(86). The latest structure in 2017 has been
solved to a resolution of 3.5Å(87)(Figure. 12). This is just one of many structures that serve as an
example for how much the field of single-particle cryo-EM has grown over the past several
decades, especially from the early 2000s until now. It continues to grow with the new
advancements in imaging and detection technology.

Figure 12: GroEL Structure. Left. negative stain EM images
Source: (85). Top right. 11.5Å structure Source: (86). Bottom
right. 3.5Å structure Source: (87).
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II. 5-Lipoxygenase (5-LOX)-5-Lipoxygenase Activating Protein (FLAP)
Nanodisc Complex
The 5-LOX enzyme and transmembrane protein FLAP have been strongly suggested to interact
and there is evidence for 5-LOX’s dependence on FLAP(33,49). Purified detergent solubilized
FLAP has not been demonstrated to interact with purified 5-LOX, suggesting that the membrane
bilayer plays a crucial role in the interaction between 5-LOX and FLAP. The interaction of 5-LOX
and FLAP has not been reconstituted in vitro until now with this work presented here. Singleparticle cryo-EM and other biochemical techniques have been used to analyze the assembly of
the 5-LOX-FLAP-ND interaction.
Nanodiscs
Nanodiscs are engineered membrane systems consisting of phospholipids encased by a
membrane scaffold protein (MSP) (54,55,88,89). Nanodiscs provide membrane proteins with a
native-like environment and cryo-EM structures of the ribosome-SecYE complex (58), the anthrax
toxin translocon-lethal factor complex (69), and intact human integrin αIIbβ3 (90) have all been
reported with nanodisc constructions. Cryo-EM structures enable larger overall structural and
functional features to be observed in a macromolecular complex. For example, an F-type ATP
synthase (91) complex provided an overall understanding of how individual components work
together, while the fine details are examined by the individual component x-ray crystal structures
docked into the complex structure. This same approach will be taken with the 5-LOX-FLAPnanodisc complex.
Nanodiscs were constructed to mimic the lipid composition of the nuclear membrane. The
nuclear envelope lipid composition is not well defined but it has been characterized based on the

Figure 13. Micrographs of Empty Nanodiscs. Left. Negative
stained nanodiscs. Right. Cryo-EM of nanodiscs.
lipid make-up of the ER membrane, which is a continuation of the nuclear membrane (92). Based
on the overall lipid composition of leukocytes, nanodiscs were designed with approximately 75%
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 25% 1-palmitoyl-2-oleoyl-sn-glycero3-phospho-L-serine (POPS), and 2% 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
(SAPC). Nanodiscs enable reconstruction of a single-particle system by cryo-EM imaging without
the need to control the direction of insertion of FLAP into the bilayer, as either side will be
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accessible to 5-LOX. The specified phospholipids and MSP are solubilized in a solution containing
cholate detergent. A longer MSP belt (MSP1E3D1) was expressed and purified, which gives
~129Å diameter nanodiscs (55). Once constructed, the nanodiscs with Histidine-tagged MSP are
purified by cobalt affinity chromatography. The homogeneity of nanodiscs is then analyzed by
negative stain EM and further analysis with cryo-EM (Figure. 13). The specific nanodiscs I have
constructed provide an environment that approximates FLAP’s native environment. Please refer
to the Materials and Methods section for a detailed outline of the nanodisc construction process.
FLAP Incorporated Nanodiscs
FLAP-incorporated nanodiscs were constructed using MSP1E3D1 and a mixture of the three
classes of phospholipids. The phospholipid mixture and MSP are solubilized in a cholate
detergent buffer. FLAP is overexpressed and purified from E. coli in n-dodecyl-ß-D-maltoside
(DDM) detergent buffer to keep it soluble. To confirm successful FLAP incorporation, FLAP
nanodiscs were immuno-gold labeled and imaged by negative stain EM (Figure. 14). As expected

Figure 14. Negative stain EM micrograph. Left. Goat anti-FLAP
immuno-gold labeled with anti-goat antibody conjugated with
10 nm gold particle. The gold covers most of the nanodisc. Black
boxed picture enlarged at right. Above. Model of the FLAP-ND
empty nanodiscs and FLAP nanodiscs do not differ in size. Since FLAP is expressed with a
Histidine-tag, FLAP occupied nanodiscs were purified on cobalt-affinity column. The histidine-tag
on MSP was cleaved off by incubation with the tobacco etch virus (TEV) protease, which
specifically recognizes a sequence of seven amino acids that allows removal of affinity tags.
Negative staining revealed views of FLAP-nanodiscs; FLAP can be seen as a single dark
impression located in the center of the nanodisc (Figure. 15). Nanodiscs provide a native-like
environment for studying FLAP’s interaction with 5-LOX and are applicable to single-particle
TEM.
Nanodiscs have been shown to maintain the active form of the protein embedded in it, especially
those that require particular lipids for their function (53). The incorporation of FLAP into
nanodiscs is accomplished during nanodisc self-assembly when detergent is removed. FLAP is
added to the cholate solution of lipids and MSP, therefore there is a mixture of detergents that are
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slowly removed by bio-beads for nanodisc formation. This mixture of detergents helps stabilize
the protein more so than cholate alone. If a membrane protein is exposed to cholate for too long it
will compromise the integrity of the protein (53,93). A single FLAP particle is embedded in a
single nanodisc, as visualized by immuno-gold labeling of FLAP in FLAP-nanodiscs constructions

Figure 15. Negative stain EM imaging of FLAP incorporated nanodiscs.
Above. FLAP-ND single particle images. Right. FLAP-ND micrograph.
in the EM. Though the FLAP trimer is suspected to be incorporated in the nanodiscs, it is possible
that it is just a monomer of FLAP. Due to the close proximity of antibody epitope binding sites it
may not be possible to bind more than one FLAP monomer at a time. Therefore, the FLAP trimer is
suspected to be what is observed in the EM.
5-LOX-FLAP-ND Interaction
The structure of 5-LOX-FLAP-nanodiscs will be determined by single-particle cryo-EM. I have
started a collaborative project with the EM National Center for Macromolecular Imaging (NCMI)

Figure 16. Model of the 5-LOXFLAP interaction.
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facility at Baylor School of Medicine. All preliminary images were taken with a JEOL 1400
microscope at the LSU Shared Instrumentation Facility. Once optimal micrographs are obtained,
they will be analyzed with three-dimensional reconstruction software, EMAN2/RELION (84,94)
that is currently running on of the supercomputers at LSU’s high-performance computing center,
remotely accessed with a lab computer. Once the complex structure is solved, the individually
known x-ray crystal structures of 5-LOX and FLAP will be docked in to the complex. This will
allow in- and out- of complex molecular differences to be analyzed, therefore providing the
details of the role of FLAP in the regulation of 5-LOX. A working model for how 5-LOX might bind
to FLAP embedded in a nanodisc bilayer is depicted in Figure 16. In this model the 5-LOX
membrane insertion loops are positioned to insert into the bilayer. The active sites of the two
components align for efficient substrate transfer.
Although cryo-EM is a new technique to Louisiana State University (LSU), we have an electron
microscope with cryo capabilities that can be used to acquire sufficient preliminary images. The
collaboration with the EM center at Baylor provides us access to a state-of-the-art detector. To
gain a better understanding of this technique I attended a three-dimensional microscopy course

Figure 17. Negative stain EM of 5-LOX-FLAP-ND. Left. Micrograph of 5-LOX-FLAP-ND with
example of the complex indicated in the black circle. Above. An enlarged image of the
complex in the black circle. The 5-LOX enzymes traced in orange and one measured to 8.9nm.
Based on the crystal structure of 5-LOX 8.9nm is the expected length of 5-LOX. FLAP-Side view
of FLAP-ND is traced in yellow.
at the University of Zurich, where I learned the theoretical and practical aspects of cryo-EM. In
order to spread awareness of what can be achieved with this technique, I organized a cryo-EM
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workshop at LSU. The workshop included outside speakers who are experts in the field. Along
with the speakers, I lectured on the basic principles of this technique and provided hands-on
sessions to familiarize interested scientists on what goes into cryo-EM. Single-particle cryo-EM is
my main focus in examining the complex structure of 5-LOX and FLAP in a membrane
environment.
Wild-type 5-LOX was overexpressed in E. coli. and purified with a modified protocol that was
modeled after the work by Kumar et al (95). 5-LOX is a challenging enzyme to purify and stabilize;
determination of the 5-LOX structure, required several mutations in order to purify and crystallize
a stable but functional enzyme (42). Wild-type 5-LOX’s short half-life along with its association
with membrane make it a difficult enzyme to isolate in active form. However, with the addition of
catalase and FeSO4 to protect the non-heme iron(95), and working quickly at cold temperatures, I
was able to purify 2.4 mgs of active enzyme from a 3 L culture, a yield which is suitable for singleparticle cryo-EM as well as functional assays.
Purified 5-LOX was incubated with the FLAP-nanodiscs, and since 5-LOX readily associates with
membrane, it has an affinity for FLAP-nanodiscs. Preliminary images of 5-LOX-FLAP-NDs were
analyzed with negative stain EM (Figure. 17). Although there is still crowding of the complex that
needs to be worked out, the 5-LOX-FLAP-ND can be seen coming together as indicated by the
black circle in the micrograph. The complex indicated in the black circle can be seen as a single
FLAP-ND with what appears to be two 5-LOX enzymes. When compared to the crystal structure of
5-LOX, the shape and length measurement of the particle at 8.9 nm is a good indicator that it is
indeed 5-LOX interacting with the FLAP-ND. This interaction is also supported by the fact that
clustering observed with 5-LOX-FLAP-ND is not seen with 5-LOX-Empty-ND (Figure. 18). Both

Figure 18. Negative stain EM 5-LOX-Empty-ND. Right.
Micrograph of 5-LOX-Empty-ND. Above. Enlarged image of 5LOX and Empty-NDs indicated in the black circle.
micrographs of 5-LOX-FLAP-ND and 5-LOX-Empty-ND were analyzed in the absence of Ca2+.
However, the addition of Ca2+ has been shown to cause stacking of NDs(96) and it is likely that
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clustering would be seen by both 5-LOX-FLAP-ND and 5-LOX-Empty-ND in the presence of Ca2+.
This suggests that the clustering of the 5-LOX-FLAP-ND seen in Figure 17 is due to the attraction
between 5-LOX and FLAP.
The interaction of 5-LOX and FLAP was also analyzed by clear native polyacrylamide gel
electrophoresis (PAGE) and western blot analysis (Figure. 19). The fading of the FLAP-ND band
with increasing ratio of 5-LOX to FLAP-ND in the anti-FLAP western blot suggests an affinity of the
two proteins for each other and is consistent with the presence of FLAP-ND in the native gel. The
amount of FLAP-ND was kept constant while increasing amounts of 5-LOX were added to the gel
(Figure. 19). Based on previous evidence of LOX’s dependence on Ca2+ to bind nanodiscs (95,97),
I examined 5-LOX’s dependency on Ca2+ for nanodisc association. Although immunofluorescence imaging of 5-LOX in HEK293 demonstrated 5-LOX’s dependence on Ca2+ for nuclear
membrane association, 5-LOX-FLAP-nanodiscs analyzed in the presence and absence of Ca2+ by
size exclusion chromatography (SEC) demonstrated similar binding affinity though it may be
possible that trace amounts of Ca2+ were still present.

Figure 19. Native PAGE and Western blot analysis of 5-LOX-FLAP-ND. Left. Native PAGE stained
with Sypro Ruby. The first lane is protein marker (not well stained by Sypro ruby) followed by
purified 5-LOX, purified FLAP, Empty-ND, FLAP-ND, 5-LOX-Empty-ND then 5-LOX-FLAP-ND at
increasing 5-LOX: FLAP-ND ratios of 0.25:1, 0.5:1, 1:1, and 2:1. Right. Western blot of native gel
on the left with development with anti-FLAP antibody. The FLAP-ND band is seen to diminish
with the increasing ratio of 5-LOX: FLAP.
AA was introduced in the nanodisc self-assembly process and preliminary data of product
generation by 5-LOX-FLAP-NDs and 5-LOX-Empty-NDs was analyzed by high pressure liquid
chromatography (HPLC). Only the intermediate product was observed by HPLC analysis (Figure.
20). However, the reduced intermediate product, 5-HETE was observed near the limit of
detection for HPLC analysis therefore product analysis of the complex is being further analyzed
by LC/MS/MS by our collaborators, the Werz lab at Jena Universität to detect possible LT
products. A functional 5-LOX-FLAP-nanodisc interaction should increase the amount of LTA4 (at
the expense of the intermediate 5-HPETE). Ca2+-dependent access to AA in liposomes has been
demonstrated by a LOX enzyme (98). Therefore, an increased attainability of AA should be
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observed with addition of Ca2+ in 5-LOX-Empty-ND. Moreover, once 5-LOX binds to the FLAPnanodiscs, it should obtain AA from FLAP, therefore the products observed are due to the 5-LOXFLAP-nanodisc interactions.
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2.50%

5-HETE

2.00%
1.50%
1.00%
0.50%
0.00%

5-LOX EMPY-ND

5-LOX FLAP-ND

Figure 20. Preliminary HPLC product
analysis of 5-LOX-FLAP-ND and 5-LOXEmpty-ND
Cryo-EM suits the question being addressed about the 5-LOX-FLAP-nanodisc complex. How 5LOX and FLAP interact with each other, as well as how they both interact with the nuclear
membrane may require dynamic movements that do not only have one orientation. With cryo-EM,
the complex will be examined in multiple conformations. Docking of the already known
individual crystal structures of 5-LOX and FLAP into this complex structure will provide both the
biochemical and biological understanding needed to conceptualize the function and regulation of
this complex in LT biosynthesis. I anticipate observing the general interaction sites of 5-LOX and
FLAP and gain information into how FLAP contributes to leukotriene biosynthesis. With this
information we could gain insight into the regulation of leukotriene biosynthesis, which will allow
us to take a further look into how this pathway functions in its known associated diseases.
Determining the structural basis for function and regulation of the 5-LOX-FLAP-ND complex, as
well as the details of substrate acquisition by the complex, is essential for understanding its role
in LT biosynthesis. Structural and functional studies of the 5-LOX-FLAP-ND complex will shed light
on how the biosynthesis of leukotrienes is regulated and therefore lead to insight on how 5-LOX
and FLAP contribute to these diseases. Cryo-EM complex data complemented with the x-ray
crystallography data of 5-LOX and FLAP will provide an enhanced perspective of the overall
mechanism of LT biosynthesis. Additionally, structural information of the 5-LOX-FLAP-ND
interaction could lead to inhibition studies for this drug target.
The complementarity of the individual crystal structures of 5-LOX and FLAP with the overall
complex structure and their interactions with the membrane enable us to understand the overall
mechanism and regulation of LT biosynthesis. Furthermore, the individual crystal structures will
provide detailed biochemical information to understand the larger conformational changes and
vice versa. The resolution and size limit of single-particle cryo-EM is being pushed everyday with
structures like the 95kDa TRPV1 ion channel at 3.4Å (75,99) and the 2.2Å structure of βgalactosidase (75,100). The increasing potential of single-particle cryo-EM makes determination
of the structure of the 5-LOX-FLAP-ND complex possible.
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III. A Specific 5-lipoxygenase Motif Impedes Enzyme Activity and Confers
Dependence on a Partner Protein
Leukotrienes (LT) are lipid mediators of the inflammatory response that play key roles in diseases
such as asthma and atherosclerosis. The precursor leukotriene A4 (LTA4) is synthesized from
arachidonic acid (AA) by 5-lipoxygenase (5-LOX), a membrane-associated enzyme, with the help
of 5-lipoxygenase-activating protein (FLAP), a nuclear transmembrane protein. In lipoxygenases
the main chain carboxylate of the C-terminus is a ligand for the non-heme iron and thus part of the

Figure 21. Structural perspective of the triple lysine motif. A. Two 5-LOX cartoon diagrams
related by a 180° rotation. The “Tail” and “Body” antibody epitopes are highlighted in green
and blue, respectively. The Triple Lysine mutant residues (ENL) are shown in stick rendering in
magenta. B. Sequence comparison of human 5-LOX and other LOXs highlighting the conserved
Arg651 (blue) and the unique 5-LOX Lys-655 where there is a highly conserved Leu (magenta).
C. The Triple Lysine Motif is located at the turn between the C-terminal helix and carboxyterminus, which is a ligand for the catalytic non-heme iron. The “Tail” epitope (green), and the
conserved Arg and Leu (blue and magenta) are depicted.
catalytic center. I investigated the role of a lysine-rich sequence (KKK653-655) 20 amino acids
upstream of the C-terminus, unique to 5-LOX, that might disrupt placement of the main-chain
carboxylate in the metal coordination sphere (Figure 21). A 5-LOX mutant in which KKK653-655 is
replaced by ENL was transfected into HEK293 cells in the absence and presence of FLAP.
Substitution of KKK with ENL leads to the formation of ~20-fold higher 5-LOX product levels in
stimulated HEK cells relative to the wild-type expressing cells. Co-expression with FLAP elevates
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product formation of wild-type 5-LOX but dramatically decreases product formation of the mutant
down to the levels of wild-type enzyme. 5-LOX product formation and enzyme levels suggest that
the KKK motif limits enzyme activity and that this attenuated activity must be compensated by the
presence of FLAP as a partner protein for effective LT biosynthesis.
The biosynthesis of leukotrienes (LT), lipid mediators of the inflammatory response, is initiated by
5-lipoxygenase (5-LOX) (23,24). 5-LOX translocates to the nuclear membrane upon intracellular
Ca2+ mobilization (25,26), along with phospholipase A2 (PLA2). PLA2 cleaves arachidonic acid
(AA) from phospholipids that form the nuclear bilayer so that it is then available for 5-LOX to be
converted to LTA4. Additionally, 5-LOX requires a helper protein, 5-lipoxygenase-activating
protein (FLAP), a nuclear membrane-embedded AA-binding protein that facilitates substrate
access and promotes completion of the two-step transformation of AA to LTA4 (16,17,33,34). This
transformation proceeds via (i) hydrogen abstraction at C7 and the oxygenation of AA at C5 and
(ii) hydrogen abstraction from the 5-hydroperoxyeicosatetraenoic acid (5-HPETE) intermediate at
C10 to generate LTA4 (27,28) (Figure. S1). 5-LOX and FLAP co-localize at the nuclear membrane
and are suggested to interact (47,101-103).
5-LOX is a short-lived enzyme (30,31,104,105), as is fitting for an enzyme that initiates the
synthesis of inflammatory compounds that activate G-protein coupled receptors at nanomolar
concentrations (13,14,106). The effects of overproduction of 5-LOX-generated lipid mediators are
exhibited in pathologies such as asthma and atherosclerosis. Auto-inactivation has been
proposed to play an important regulatory role in temporal control of 5-LOX activity (107,108).
Enzyme lability, whether a consequence of turnover or non-turnover-based inactivation, can
serve as an auto-shutoff valve, an innate “intrinsic regulator.” Auto-inactivation that is a
consequence of protein (in)stability has been described as a mechanism for temporal control of
protein function in other systems. For example, the short half-life of the activated, mature
protease Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa) ensures a short burst of activity.
TAFI circulates as the zymogen, but once processed by thrombin, its half-life is on the order of
minutes (109). This instability can be defined as a functional or structural instability of the protein.
It has been observed that residues of an enzyme that are vital for its function do not contribute to
the structural stability of the enzyme, rather to its structural instability. A study by Shoichet et al.
demonstrated that mutating specific residues in the active site of the T4 lysozyme depleted the
enzyme’s activity but increased its structural stability (110). Here we describe such a system
where a specific sequence mutation incites structural stability, however only functional instability
in relation to the balance of leukotriene biosynthesis. It is important to note that the
overproduction of 5-LOX products can lead to the detrimental effects of over-inflammation, thus I
will define functional stability in terms of functional output of the 5-LOX enzyme.
Why a Triple Lysine Motif?
We asked whether 5-LOX might harbor a unique structural feature in the canonical LOX fold
(there are six different LOX isoforms in humans) that might provide a structural basis for its short
life span and we identified a unique sequence motif (KKK653-655) that confers enzyme structural
instability in vitro. Indeed, replacement of KKK653-655 with its counterpart from a stable 5-LOX
homologue (i.e. ENL, in an expression construct trimmed of its membrane-insertion loops)
allowed us to obtain the crystal structure of so-called Stable-5-LOX (42). The structural basis for
KKK-invoked instability is easy to rationalize: the presence of K655 (where LOX counterparts have
a Leu) positions a charged amino acid for repulsion with the invariant Arg-651 (Figure. 21). The
structure of a bacterial LOX that harbors an Arg at the Leu position confirmed this prediction: the
invariant Arg that participates in a conserved salt link has been displaced in this enzyme (111).
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The carboxy termini of LOXs insert into the catalytic domains so that the terminal, backbone
carboxyl serves as a ligand for the catalytic iron. The KKK653-655 sequence in 5-LOX is located in a
turn 20 amino acids upstream of the carboxylate-ligand and its presence may make it difficult to
insert the “tail” of the enzyme into the active site. Substitution of KKK653-655 with ENL leads to a
variant (Tri-Lysine Mutant, TKM-5-LOX) that is resistant to cleavage by chymotrypsin in vitro in
conditions in which the wild-type enzyme is rapidly digested. TKM-5-LOX retains the ability to
translocate to the membrane and to co-localize with FLAP in HEK cells. Of interest, we observed
that HEK cells expressing TKM-5-LOX display a ~20-fold increase of 5-LOX product formation
relative to wild-type enzyme. In parallel experiments with Ca2+-ionophore-stimulated cells we
see an accelerated loss of TKM-5-LOX, so the mutant enzyme is still subject to turnover-based
inactivation. However, when co-expressed with FLAP, 5-LOX products detected in HEK cells for
both the mutant and wild-type enzyme are equivalent, an indication that the KKK motif is not
critical for modulation of 5-LOX activity by FLAP. Our data suggest that the KKK motif is a
governor of 5-LOX enzyme activity; the helper protein FLAP is required to sufficiently relieve its
auto-suppression for effective LT synthesis.
Results
Purified WT-5-LOX and TKM-5-LOX were subjected to limited proteolysis by chymotrypsin. The
enzymes were incubated with the protease in the absence and presence of Ca2+. TKM-5-LOX

Figure 22. In vitro chymotrypsin cleavage analysis. WT-5LOX and TKM-5-LOX cleavage patterns with “Body” (left)
or “Tail” (right) antibody development, +/- Ca2+ and/or
chymotrypsin. WT-5-LOX displays susceptibility to
chymotrypsin cleavage, while TKM-5-LOX is strikingly
more resistant. The lane containing the molecular weight
markers is labelled “mwm.”
exhibited a higher resistance to cleavage by chymotrypsin than WT-5-LOX when the proteins
were assessed with two distinct antibodies: one specific for the C-terminal twelve amino acids
(“Tail”) and the other for amino acids 130-149 (“Body”) (Figure. 22, antibody epitopes
highlighted in Figure. 21). Essentially, little to none of the full-length enzyme was detected by
either antibody when WT-5-LOX was incubated with chymotrypsin. In contrast, TKM-5-LOX
remained largely intact in these same conditions. Interestingly, Ca2+, which binds to the amino
terminal membrane-binding domain, seems to minimize the presence of a low molecular weight
band derived from the C-terminus for both enzymes and to retain a trace amount of the full-length
enzyme of WT-5-LOX.
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The major band detected for the TKM-5-LOX after exposure to protease is likely to be full-length
enzyme given that it is recognized by an antibody raised to the C-terminal peptide and migrates
at the same molecular weight as the purified enzyme.
The TKM-enzyme is also more resistant to chymotrypsin in cell lysates. The lysates of HEK cell
expressing WT- and TKM-5-LOX (but not FLAP) were incubated with chymotrypsin, with and
without A23187 Ca2+-ionophore. The products of the incubations were analyzed by Western blot

Figure
23.
Chymotrypsin
cleavage of 5-LOX in lysates of
transfected HEK 293 cells.
Chymotrypsin cleavage patterns
from lysates of HEK cells
expressing WT-5-LOX or TKM-5LOX. Each was analyzed +/Ca2+-ionophore
(A21387)
stimulation and developed with
the “Tail” primary antibody.
Lanes labeled “mwm” and “UT”
correspond to the molecular
weight markers and lysates of
untransfected cells, respectively.
Note the intensity of the lower
molecular
weight
band
generated by chymotrypsin for
the WT enzyme, relative to the
full-length band.
using the Tail antibody. It is important to note that the cleavage bands observed in samples
incubated without chymotrypsin demonstrate the enzyme’s susceptibility to activated cellular
proteases upon lysis of the cell as lysates did not contain protease inhibitors. Fragments detected
for WT enzyme are more pronounced than in the lysates of TKM-expressing cells (Figure. 23).
Immunofluorescence microscopy studies indicate that like the wild-type protein, the TKM-5-LOX
variant translocates to the nuclear membrane upon stimulation with Ca2+ ionophore, both in the
absence and presence of FLAP (Figure. 24).
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Detection by both Body and Tail antibody demonstrated that TKM-5-LOX colocalizes with FLAP, as
seen for the wild-type enzyme (Figure. S2). Additionally, the mutant displays the same
cytoplasmic localization as the wild-type when unstimulated (Figure. 24).
A

-FLAP
Unstimulated

Stimulated

B

+FLAP
Stimulated

Figure 24. Cellular localization of 5-LOX variants in HEK 293 cells. A. WT-5-LOX and TKM5-LOX expressing HEK cells in the absence (unstimulated) and presence (stimulated) of
Ca2+-ionophore A23187, developed with “Body” or “Tail” primary antibodies. The nucleus
is indicated by DAPI (blue) and 5-LOX by AlexaFluor-488 (green). In the absence of Ca2+ionophore the enzymes are dispersed in the nucleus and cytoplasm. Once stimulated clear
“rings” surround the nuclear DNA staining. B. When expressed with FLAP, both WT-5-LOX
and TKM-5-LOX co-localize with FLAP in the presence of Ca2+-ionophore A23187, as
detected with either “Body” or “Tail” primary antibodies. FLAP is imaged with AlexaFluor647 (red). Combined TRITC and Cy5 channels demonstrated colocalization of 5-LOX and
FLAP at the nuclear membrane as confirmed by ImageJ colocalization analysis.
TKM-5-LOX was expressed in HEK293 cells at levels comparable to the WT-5-LOX, as judged by
mRNA and protein levels, detected by qPCR (Figure. S3) and Western blotting, respectively (vida
infra). 5-LOX-expressing HEK cells devoid of FLAP were incubated with or without Ca2+ionophore A23187 in the presence of 3 μM AA. At this concentration of AA the bulk of the
substrate is expected to partition into the bilayer and is only accessible to 5-LOX once the
enzyme translocates to the membrane. Both the final LTA4 hydrolysis products and the
intermediate 5-HPETE (which is detected as the reduced alcohol 5-hydroxyeicosatetraenoic acid,
5-HETE) were quantitated by high-pressure liquid chromatography (HPLC) analyses. As
expected, 5-LOX product formation was only detected once cells were stimulated with Ca2+ionophore. In the absence of FLAP, TKM-5-LOX-expressing cells yielded strikingly (~20-fold)
higher overall product compared to WT-5-LOX cells (Fig. 25). However, the proportion of LTA4
hydrolysis products relative to the intermediate 5-HETE is roughly the same (~30%). This ~20-fold
higher product formation is not due to elevated protein expression levels (vida infra) and
indicates that TKM-5-LOX has significantly improved or prolonged enzyme activity over WT-5LOX.
In agreement with previous findings (32), co-expression of FLAP in HEK cells together with 5-LOX
caused a ~4-fold increase in product formation by the WT enzyme (Figure. 25). In contrast, co28

expression of FLAP reduced product formation of TKM-5-LOX down to the levels of WT-5-LOX.
There is, however, a difference in the relative amounts of LTA4 hydrolysis products vs. 5-HETE
detected, with the TKM-5-LOX yielding a higher ratio (~60%) of final product than WT-5-LOX
(~30%). While the presence of FLAP attenuates the increased activity of TKM-5-LOX, it promotes
completion of the two-step reaction catalyzed by TKM-5-LOX.
A

B

C

Figure 25. 5-LOX activity in HEK 293 cells. A. The TKM mutant displays a robust activity in
HEK cells. WT-5- LOX and TKM-5-LOX +/-FLAP HEK cells (with Ca2+-ionophore stimulation)
were incubated with 3μM AA. Leukotrienes (gray), 5-HETE (black) as detected by HPLC
analysis of cell lysates. (Product was not detected in the absence of Ca2+-ionophore.) TKM-5LOX exhibits a significant increase in product relative to WT-5-LOX. B. The extent of reaction
completion in intact cells. The graph displays the level of LTA4 detected relative to the 5HPETE intermediate. WT-5-LOX and TKM-5-LOX without FLAP have equivalent LT/5-HPETE
ratios but with FLAP the mutant has a modest increase in the proportion of LTA4 hydrolysis
products detected by HPLC. C. The striking increase in activity of the TKM variant is not
observed in cell homogenates. The activities of the WT and mutant enzyme are comparable
when assayed in cell homogenates.
We next monitored the 5-LOX protein levels in the HEK cells in order to investigate whether the
substitution of KKK with ENL conferred increased enzyme longevity, as might be inferred from
enzyme decay profiles. Using a method adapted from that described by Dai et al.(112), 5-LOX
protein levels (relative to the house-keeping protein GAPDH) in the presence of the protein
synthesis inhibitor cycloheximide were monitored in HEK cells for four hours by Western blot. In
addition, these experiments were repeated in the presence of Ca2+-ionophore A23187 under
conditions where 5-LOX becomes activated and translocates to the nuclear membrane (Figure.
26) to access free AA.
In the absence of FLAP and Ca2+-ionophore, the levels of WT- and TKM-5-LOX remained roughly
stable up to 4 h, regardless of the presence of FLAP. In these conditions, the WT-5-LOX appears to
be expressed at slightly elevated levels (Fig 26). However, upon Ca2+-ionophore stimulation of
cells devoid of FLAP, the levels of the TKM-5-LOX rapidly declined, while that for the WT-5-LOX
remained stable. Thus, the rapid disappearance of TKM-5-LOX is consistent with its enhanced
enzyme activity/high turnover which contributes to the enzyme’s functional instability. In contrast,
when co-expressed with FLAP, where 5-LOX product levels of WT and mutant enzyme are
comparable, the levels of TKM-5-LOX remain stable.
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Figure 26. In the absence of protein synthesis WT enzyme levels remains constant in HEK 293.
A. Western blots of WT- and TKM-5-LOX. WT-5-LOX and TKM-5-LOX +/- FLAP –expressing
HEK cells incubated with cycloheximide over a four hour period. Westerns for both 5-LOX and
the housekeeping enzyme GAPDH (lower panel) at time points 0, 60, 90, 120, 150, 180, 210,
and 240 min in the absence (top) and presence (bottom) of Ca2+- ionophore A21387 were
developed with “Tail” antibody. Both mutant and wild-type levels remain stable in the
absence of Ca2+-ionophore. Post-stimulation TKM-5-LOX levels decline rapidly when FLAP is
absent. Representative Westerns are depicted for each of the experiments. B.
Triplicate/duplicate plots (black, gray and white circles) of the ratio of 5-LOX to GAPDH
levels, as determined from band densities. Although differences in expression levels are
observed between duplicate and triplicate experiments, the trends are equivalent.
Cycloheximide is not stable for the entire time period, and was replenished at 120 minutes.
Quantification of 5- LOX variants was measured relative to GAPDH density by ImageJ. Only
TKM-5-LOX, when expressed in the absence of FLAP, displays a significant decline in enzyme
detected in the first hour after stimulation.

Intrinsic Regulators
The KKK653-655 sequence is located 20-amino acids up stream of the C-terminal Ile-673, which
ligates the active site iron via its carboxyl moiety. This unique sequence motif appears to conflict
with stabilizing salt-link and π-cation interactions observed in other (more stable) LOX structures.
K655 of the KKK motif in other LOXs is typically a conserved Leu. A highly conserved Arg-651 lies
one turn away on the C-terminal helix and participates in a conserved salt-link with Asp-473 and a
cation-π interaction with Phe-469 (42). Thus, a Lys at 655 in WT-5-LOX may disrupt these
stabilizing interactions and impact the positioning of the C-terminal carboxyl in the Fe2+
coordination sphere. The mutation of the KKK to ENL was performed to stabilize 5-LOX for
crystallographic studies, and it was observed that the mutation increased the melting
temperature of the protein (42). This led us to suggest that the motif might act as an “intrinsic
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regulator” by accelerating enzyme inactivation in the absence of substrate, as 5-LOX has an
atypically short half-life compared to other LOXs (107). TKM-5-LOX is less susceptible to protease
as the purified enzyme, or in crude cell lysates. However, we observed that the levels of both WT5-LOX and TKM-5-LOX remain stable in HEK cells when substrate is not available. On the other
hand, the KKK sequence significantly tempers an otherwise robust enzyme activity.
I have demonstrated that the KKK653-655 sequence is a unique 5-LOX structural feature that acts as
an intrinsic regulator of 5-LOX to control the flow of LT biosynthesis. In the absence of FLAP, I
observed a striking difference in the activity of the WT- and TKM-5-LOX. The KKK motif severely
constrains a robust LOX activity as observed by the ~20-fold increase in product formation when
the KKK sequence is substituted by ENL (Fig. 25). However, this increase in activity is not
apparent when TKM-5-LOX is co-expressed with FLAP. In these conditions, 5-LOX product levels
of WT- and TKM-5-LOX are equivalent. While the presence of FLAP increases the LT biosynthetic
capacity of the WT-5-LOX-expressing cells, the TKM-5-LOX-expressing cells display a
significantly reduced LT biosynthetic efficiency when FLAP is present.
FLAP is able to compensate for the lower activity of the WT-5-LOX to some extent. Thus, we
suggest that the KKK motif confers the requirement for FLAP for the rapid initiation of LT
biosynthesis. This regulatory mechanism is reminiscent of the cyclin/cyclin-dependent kinase
scenario, where an enzyme (the kinase) requires interaction with a binding partner to promote
catalytic competence (113). Overproduction of LTs as pro-inflammatory mediators is detrimental
to the organism, thus the tempered activity of 5-LOX that relies on alleviation by a protein partner
limits this possibility. WT-5-LOX alone is particularly inefficient at producing lipid mediators, but
stimulated by FLAP it still does not reach the levels produced by the TKM-5-LOX expressed
without FLAP. Thus, we interpret TKM-5-LOX’s high level of product output as a functional
instability in respect to LT biosynthetic pathway efficiency. The fact that FLAP prevents the
marked increase in 5-LOX product formation by TKM-5-LOX suggests that the KKK motif is not
required for interaction with FLAP.
By monitoring enzyme levels in the presence of an inhibitor of protein biosynthesis, we observed
turnover-dependent inactivation of 5-LOX. In the absence of Ca2+-ionophore, both WT- and TKM5-LOX exhibited stable protein levels. However, in the presence of Ca2+-ionophore there is a
rapid decline in the level of TKM-5-LOX in the cell (Fig. 26). The cycloheximide analysis was
performed without addition of exogenous AA, however, we can detect the products of TKM-5-LOX
activity (expressed in the presence of FLAP) in Ca2+-ionophore-stimulated HEK cells without the
addition of exogenous AA (Fig. S4). The presence of endogenous phospholipid-esterified AA that
might provide a source of substrate is supported by data from other groups. Dawaliby et al
established that HEK293 cell membranes contain C20 containing phospholipids (114). More
specifically, Zhu et al (115) report the presence of 20:4n-6 fatty acids in the cell membrane
phospholipids of HEK293 cells. Additionally, HEK cells transfected to express 12-LOX generate
product without the addition of exogenous AA when cultured in DMEM (32). Therefore, the
elevated product levels detected in HEK cells expressing TKM-5-LOX in the presence of
exogenous AA and the rapid decay of TKM-5-LOX once stimulated with Ca2+-ionophore to
promote release of endogenous PL-esterified AA are consistent with turnover-based inactivation.
Other examples of auto-inactivation conferred by a specific sequence motif include one
described by Fenalti et al. The flexibility of a catalytic loop in a particular isoform of glutamic acid
decarboxylase (GAD65) enables the release of cofactor and therefore subsequent inactivation of
the enzyme (116). Specific integral protein sequence motifs may act as a “kill switch” to allow
modulation of enzyme activity. Although the KKK bears resemblance to other inactivation motifs,
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in this case the effects of the “kill switch” are partially negated by a partner protein that
compensates for the switch so that LT biosynthesis functions at effective levels.
The KKK motif might be an integral deactivation sequence that acts as a regulator of LT
biosynthesis. Internal enzyme fail-safe mechanisms are one of many regulatory mechanisms that
keep the intricate web of biosynthetic pathways in check. An intriguing auto-inactivation
mechanism of another LT biosynthetic enzyme has been described for LTA4 hydrolase. In this
enzyme, the presence of Tyr-378 makes it susceptible to covalent modification by its reactive
substrate. Substitution of Tyr-378 with Gln or Ala leads to a variant less susceptible to covalent
modification, and consequently inactivation, by the substrate (117-119). Thus, both 5-LOX and
LTA4 hydrolase display auto-suppression of catalytic activity, but through entirely different
mechanisms.
Other amino acids in 5-LOX have been demonstrated to play a significant role in tempering a
robust rate of product formation. Rakonjac et al. examined the significance of a salt-link between
residues R101 and D166 of the regulatory and catalytic domains, respectively. Disruption of this
interaction leads to an increase in enzyme activity (120).
Our studies do not reveal exactly how the presence of the KKK motif modulates 5-LOX activity.
Computational methods, as summarized by O’Rourke et al, can be combined with X-ray data to
reveal possible internal protein communication networks (121). However, the lack of a highresolution native 5-LOX structure makes this approach inaccessible at this point. In any case, it is
apparent that the KKK motif significantly contributes to tight regulation of 5-LOX activity as the
initiator of LT biosynthesis. This motif, which initially we studied as a possible destabilization
mechanism that limits protein half-life, appears to be part of a more intricate, finely-tuned control
mechanism to regulate LT biosynthesis in conjunction with FLAP.
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IV. Allosteric Inhibition of 5-Lipoxygenase (5-LOX) and Impairment of
Substrate Access from 5-Lipoxygenase Activating Protein (FLAP) by 11-Aceytlketo-beta Boswellic Acid (AKBA)
Leukotrienes (LT) are lipid mediators of the inflammatory response that play key roles in diseases
such as asthma and atherosclerosis. The precursor leukotriene A4 (LTA4) is synthesized from
arachidonic acid (AA) by 5-lipoxygenase (5-LOX), a membrane-associated enzyme, with the help
of 5-lipoxygenase-activating protein (FLAP), a nuclear transmembrane protein. Upon Ca2+
stimulation 5-LOX translocates to the nuclear membrane where the substrate-binding helper
protein FLAP resides. The natural product 3-Acetyl-11-Keto-beta Boswellic Acid (AKBA),
specifically found in frankincense, is a well-known non-competitive inhibitor of 5-LOX. We
investigated aspects of the mechanism of inhibition of 5-LOX by AKBA and solved the first crystal
structure of Stable-5-LOX in complex with an inhibitor. We define a novel allosteric binding site
wedged between the membrane-binding and catalytic domains of 5-LOX, ~30 Å from the active
site iron. Both in vitro and in 5-LOX expressing HEK cells, the absence of FLAP shifts the regiospecificity of 5-LOX to catalyze 12-HPETE formation at the expense of 5-HPETE. However, in the
presence of FLAP, AKBA effectively blocks the initiation of leukotriene production in HEK cells.
Additionally, immuno-fluorescence microscopy demonstrated a decrease in colocalization of 5LOX and FLAP at the HEK cell nuclear membrane in the presence of AKBA, while native gel
analysis of the in vitro complex of 5-LOX-FLAP-incorporated nanodisc displayed a decreased
association of the two components in the presence of AKBA. This work suggests a novel approach
to isoform-specific 5-LOX inhibitor development through exploitation of an allosteric site in 5-LOX
which interferes with its ability to obtain its substrate from FLAP.
What Is AKBA?
The anti-inflammatory properties of frankincense have been well documented(122,123), and the
active ingredient 3-Acetyl-11-Keto-beta Boswellic Acid (AKBA) was shown to be an effective non-

Figure 27. 3.0Å resolution structure of Stable-5-LOX with AKBA bound. Top left.
Cartoon rendering of structure. Bottom left. Space filling model. Top right.
Chemical structure of AKBA. Bottom right. Coordination of AKBA in the allosteric
binding site of Stable-5-LOX. (crystal structure solved by Nathaniel Gilbert)
competitive inhibitor of 5-lipoxygenase (124-126). Mechanistic details of its mode of action can
reveal novel vulnerabilities to be exploited for modulation of LT biosynthesis. We report that the
33

effects of AKBA on 5-LOX activity in the absence or presence of its helper protein FLAP differ, and
show that AKBA may interfere with the 5-LOX-FLAP interaction at the nuclear membrane. Data
obtained from 5-LOX expressing HEK cells and from polarized macrophages suggest that AKBA
may provoke a shift in the regio-specificity of 5-LOX. Moreover, we describe the first co-crystal
structure of an inhibitor with 5-LOX (Figure. 27). This allosteric binding site, wedged between the
membrane-binding and catalytic domains, lies some 30 Å from the catalytic iron.
AKBA is an allosteric inhibitor of 5-LOX that binds in a deep groove at the interface of the
membrane binding and catalytic domains. The polar groups of AKBA are positioned to H-bond
with the side chains of H130, R101, and T137, and main chain atoms of E108 and V110. This model
is entirely consistent with the structure activity relationship defined by Salier et al. with leukocytes
(127). In their cell-free assays they demonstrated the essentiality of the C-ring keto group and Aring carboxylate of AKBA; both groups can participate in H-bond to 5-LOX. Subsequent work
from the same group demonstrated that AKBA with the A-ring acetoxy group replaced with a 4azido-5-iodo-salicyloyl-beta-alanyl moiety can be cross-linked to 5-LOX (124). This bulky,
reactive group extends AKBA lengthwise to penetrate deeper into a cave-like gap between the
two domains, as the domain interface is not tightly packed (Figure. 27). Although a similar groove
at the membrane-binding –catalytic domain interface is present in the homologous enzyme 15LOX-2, each of the H-bond donors differs (Q108 for R101, Q136 for H130, A144 for T137) and the
groove is constricted at the C-ring by a charge pair that spans it (R68, W140). Accordingly, we
did not observe inhibition by AKBA at equivalent concentrations in HEK cells expressing 15-LOX2 (Figure. 29).
Results
LTA4 and 5-HETE production were monitored in HEK cells expressing 5-LOX or 5-LOX and
FLAP(32). These artificial constructs allow us to evaluate the role of FLAP in the inhibition by
A

B
-FLAP

C
+ FLAP

Figure 28. Product analysis of 5-LOX in HEK293 cells. Incubations of AKBA at 0, 25, 50, 75 and
100µM. A. 5-LOX expressing HEK cells. B 5-LOX-FLAP expressing HEK cells. C. 12-HETE/5HETE ratio of products from 5-LOX expressing cells.
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AKBA. We found that at 25 µM AKBA, 5-LOX activity was reduced by 50% in intact cells
expressing both FLAP and 5-LOX, in agreement with what has been observed in crude cell-free
assays (human recombinant 5-LO, leukocytes lysates IC50 = 15 - 50 µM) (128)) and in intact
primary neutrophils (IC50 = 3.2 µM (129)). In contrast, in HEK cells expressing only 5-LOX the
addition of AKBA led to increasing levels of 12-HydroxyEicosaTetraEnoic acid (12-HETE), at the
expense of 5-HETE, in the HEK cells (Figure. 28,29). (The hydroperoxy products are reduced
prior to HPLC analysis.) This observation suggests that AKBA only functions as a typical and
potent enzyme inhibitor when 5-LOX interacts with FLAP at the nuclear membrane to obtain
substrate. In addition, we asked whether AKBA might also modulate the activity of 15-LOX-2, its
closest intra-species orthologue. The amount of 15-HETE detected in the extracts of 15-LOX-2
expressing cells was unchanged by the addition of AKBA at concentrations up to 100 µM (Figure.
29).

Absorbance (mAU)

We monitored the co-localization of 5-LOX with FLAP upon Ca2+-stimulation, which promotes 5LOX translocation to the nuclear membrane in 5-LOX expressing HEK cells regardless of whether

Retention Time (min)

Figure 29. Left. HETE profiles from HEK WT-5-LOX incubations with AKBA.
Right. Product Analysis of 15-LOX-2 expressing HEK293 cells. 15-HETE
levels analyzed at 0, 25, 50, 75 and 100 µM AKBA incubations.
FLAP is co-expressed (32). At inhibitory concentrations of AKBA, immuno-fluorescence assays
indicate that 5-LOX traffics to the nuclear membrane, but the overlay of FLAP and 5-LOX is
qualitatively different from the overlay in the absence of AKBA. Colocalization analysis suggests a
weaker correlation between the two antibodies used for detection (rabbit anti-5-LOX vs. goat
anti-FLAP). This difference can be appreciated in Figure 30. The fact that AKBA-inhibition of 5LOX is observed only in the presence of FLAP might suggest that the inhibitor functions by
interfering with the enzyme’s ability to obtain its substrate from the helper protein. When FLAP is
not present, the presence of 12-HETE in the HEK cell extracts suggests that AKBA does not
interfere with access to substrate, but modulates the enzyme regio-specificity. i.e. 12-HETE
formation is promoted at the expense of 5-HETE formation.
Additionally, chymotrypsin cleavage patterns of WT-5-LOX were monitored in vitro in the
presence of AKBA. Cleavage bands were detected by two different rabbit anti-5-LOX primary
antibodies. One to the surface epitiope of 5-LOX called “body” antibody and one to the Cterminal end of 5-LOX called “tail” anti-body. The secondary antibody, donkey anti-rabbit
Alexafluor 647 was detected with fluorescence imaging. Development with both tail and body
antibodies displayed a decrease in particular 5-LOX cleavage bands with increasing
concentrations of AKBA (Figure. 31) This could be attributed to a slight increase in structural
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stabilty of 5-LOX with AKBA bound. AKBA bound between the membrane binding domain and
catalytic domain may limit the flexibilty that 5-LOX may need for a proper interaction with FLAP.
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5-LOX + FLAP
Overlay

FLAP
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AKBA
(DMSO)
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AKBA
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AKBA

75µM
AKBA

100µM
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Figure 30. Immuno-fluorescence microscopy of 5-LOX-FLAP expressing
HEK293 cells. Cells were stimulated with Ca2+ ionophore A23187. The
nucleus is indicated by DAPI. 5-LOX is demonstrated in green by a
donkey anti-rabbit Alexafluor 488 and FLAP by donkey anti-goat
Alexafluor 647. Consequently, imaged with TRITC and Cy5 filters. Cells
were incubated with 0, 25, 50, 75 or 100µM AKBA.
An in vitro 5-LOX-FLAP complex was formed by incorporation of FLAP into a membrane mimic. It
has been inferred that the membrane plays an essential role in the interaction between 5-LOX and
FLAP. FLAP was incorporated into the engineered membrane system known as nanodiscs. The 5+ Chymo

+ Chymo

+ Ca2

+ Ca2
μM AKBA
mwm

0

0

0

0
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Figure 31. In vitro Chymotrypsin cleavage of WT-5-LOX. Cleavage analysis of 5-LOX in the
presence of AKBA at 0, 50, 75 and 100 µM. Left. Western blot development with anti-5-LOX
body antibody. Right. Western blot development with anti-5-LOX tail antibody. The westerns
indicate the fading cleavage bands with increasing AKBA concentrations.
LOX and FLAP-Nanodisc (ND) interaction was monitored by clear native gel analysis in the
presence of increasing concentrations of AKBA (Figure. 32). 5-LOX and FLAP-ND were incubated
at a 1:1 ratio. Note that when 5-LOX is added to the FLAP-ND incubations the dark band shifts
upward (lane 5). With addition of increasing concentrations of AKBA this trend is reversed. Band
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density analysis demonstrated an increase in the FLAP-ND band in the 5-LOX-FLAP-ND
incubations as AKBA concentrations are increased. The FLAP-ND control was loaded at an
equivalent level to FLAP-ND in the 5-LOX-FLAP-ND incubations. This data suggests that AKBA may
interfere with 5-LOXs ability to interact with FLAP. Therefore, this impairment of 5-LOX to interact
with FLAP would eliminate 5-LOX’s ability to access substrate from FLAP therefore halting the
initiation of LT biosynthesis.
Our results suggest that when AKBA is bound the regio-specificity 5-LOX is compromised, as well
as its interaction with FLAP. The latter process may dominate in a cellular context, since the
alternate product regio-specificity (12-HPETE) is not observed in the presence of FLAP in the HEK

Figure 32. Native gel Analysis of 5-LOX-FLAP-ND. Left. Native gel
stained with Sypro ruby. Includes 5-LOX only, FLAP only, Empty-ND,
FLAP-ND, and 5-LOX-FLAP-ND at 1:1 ratio incubated with increasing
concentrations of AKBA (0, 25, 50, 75 and 100 µM) Top right. Section of
gel boxed in yellow displaying FLAP-ND bands. Bottom right. ImageJ
density analysis of FLAP-ND bands.
cells. However, when polarized macrophages expressing both 5-LOX and FLAP are treated with
AKBA, both inhibition of LT production and an increase in 12-HPETE are observed (Data from Jana
Gerstmeier). A confounding aspect of the macrophage experiments is the presence of 15-HPETE
in the M1 macrophage extracts. However, the LC-MS-MS does not distinguish between 15-SHPETE and 15-R-HPETE which is produced by Cyclooxygenase.
Impairment of Substrate Access from FLAP and Change in Product Specificity
We have demonstrated that the binding of AKBA to 5-LOX inhibits 5-LOX’s access to its substrate,
AA, from FLAP. FLAP is an AA-binding protein that would sequester nearby AA that has been
cleaved out of the nuclear membrane by phospholipase A2 (PLA2). Therefore, this data suggests
that a 5-LOX and FLAP interaction could be necessary for the initiation of LT biosynthesis and that
the binding of AKBA to 5-LOX disrupts this interaction. In the absence of FLAP, 5-LOX still has
access to the substrate directly from the nuclear membrane and therefore has the ability to
produce product. However, the binding of AKBA to 5-LOX may induce a conformational change
that affects the organization of the catalytic components in a way that favors the production of 12HPETE over 5-HPETE.
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Upstream of the amino terminal end of helix-α2 is R165, which makes a cation-pi interaction with
W102 of the membrane-binding domain. This highly conserved cation-pi interaction, which is
suggested to serve as a communication link between the membrane binding and catalytic
domains (130), is disrupted in the AKBA-5-LOX structure. Structural differences near helix-α2
could affect active site access and the enzyme’s interaction with FLAP, which presumably must
“deliver” the substrate to an open cavity. Moreover, it can impact the regio-specificity of the
enzyme by modulating the flexibility of this segment that must undergo a conformational change
for substrate to be positioned at the catalytic machinery. The successive reactions catalyzed by 5LOX (conversion of the substrate to the 5-hydroperoxy derivative and transformation of the
intermediate to LTA4.) are both initiated by H abstraction from a pentadiene: in the first 5-LOX
attacks C7, and the second C10(107). The 12-HPETE isomer would be generated if 5-LOX were to
attack C10 first. The presence of AKBA may simply favor a conformation of the active site in which
C10 is positioned between the active site iron and the O2 pocket that lie at the base of the “Ushaped” site.
The AKBA allosteric site establishes a template for the design of inhibitors that function by
restricting 5-LOX from accessing its full repertoire of conformational states. Moreover, as the
presence of FLAP is essential for the full inhibitory effect of AKBA, and only 5-LOX utilizes the
helper protein, exploitation of the AKBA binding groove may be a potent strategy for isoformspecific inhibition.
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V. Preliminary Studies of the Inhibition of 5-LOX by J147 and CNB-001
Alzheimer’s disease (AD) is a neurodegenerative disease in which the accumulation of amyloidlike proteins in neurons cause nerve cell death. This is primarily exhibited in older adults as the
increase in accumulation of the proteins is associated with increased age. The buildup of amyloidlike proteins induces the inflammatory response and the increase in the protein amyloid beta
(Ab) has been demonstrated to cause an increase in eicosanoids, including the pro-inflammatory
leukotrienes (LTs) (131). The initiation of the inflammatory response by amyloid-like proteins may
be a contributor to the progression of AD by enhancing nerve cell death. Thus, targeting 5lipoxygenase (5-LOX), the initiator of LT biosynthesis could have a positive effect on combating
the progression of AD.
What Are J147 and CNB-001?
Both J147 and CNB-001 are compounds that have demonstrated promise for treatment of
Alzheimer’s disease (AD). CNB-001 and J147 are compounds that have been derived from the
natural product curcumin, which has demonstrated positive results in the fight against AD (132).
CNB-001, which has a similar structure to other 5-LOX inhibitors, is a pyrazole derivative of
curcumin and J147 is derived from the CNB-001 compound. AD mouse studies with CNB-001
demonstrated better neuroprotective properties over curcumin, while J147 proved to have even
more effective neuroprotection and exhibited effects of an increase in brain derived neurotropic
factor (BDNF), as well as a reduction in inflammation and oxidative stress (132). Both of these
compounds have been shown to inhibit 5-LOX. Stress on the endoplasmic reticulum (ER) has been
suggested to play a crucial role in AD, and 5-LOX may have a part in that stress accumulation
(133). Inhibition of 5-LOX by CNB-001 has been demonstrated to decrease amyloid beta (Ab)
formation and cell death in MC65 cells(131). However, the mechanism of action between 5-LOX
and AD is not yet understood. The initial trigger of the inflammatory response by amyloid-like
proteins may enhance the early cell damage caused by the aggregation of these proteins.
Results
HEK293 cells transfected with 5-LOX were analyzed for 5-LOX activity in the presence of either
J147 or CNB-001. 5-LOX products were analyzed by HPLC analysis. 5-LOX activity was measured

Figure 33. HLPC product analysis of 5-LOX expressing HEK293 cells with incubation
of 50 µM J147 or CNB-001.
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both in the absence and presence of stimulation by calcium ionophore A23187. CNB-001
displayed complete 5-LOX inhibition at 50µM both in the absence and presence of calcium
ionophore stimulation (Figure. 33). J147 at this same concentration demonstrated complete
inhibition of 5-LOX in the absence of calcium ionophore stimulation but only partial inhibition
when 5-LOX expressing HEK cells were stimulated with calcium ionophore.
Immuno-fluorescence (IF) microscopy was employed to characterize the effect of either J147 or
CNB-001 on the localization of 5-LOX to the nuclear membrane and colocalization of 5-LOX and
DAPI
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5-LOX
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CNB-001

J147

Figure 34. Immuno-fluorescence microscopy of 5-LOX expressing HEK293 cells
incubated with J147 or CNB-001. DAPI staining depicts the nucleus. Green (Alexfluor
488 detected with GFP filter) represents 5-LOX.
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Figure 35. Immuno-fluorescence microscopy of 5-LOX-FLAP expressing HEK293
cells incubated with J147 and CNB-001. DAPI depicts the nucleus. Green (GFP filter)
represents 5-LOX and red (Cy5 filter) represents FLAP.
FLAP. HEK cells were incubated at 50 µM of either J147 or CNB-001. Rabbit anti-5-LOX and goat
anti-FLAP antibodies were used to detect each protein and secondary antibodies donkey anti40

rabbit Alexfluor 488 and donkey anti-goat Alexfluor 647 were observed by IF microscopy. In 5LOX only expressing cells which were stimulated with calcium ionophore A23187, incubations
with J147 and CNB-001 did not disrupt 5-LOX localization to the nuclear membrane (Figure. 34).
In HEK cells expressing both 5-LOX and FLAP, 5-LOX localization to the nuclear membrane and
colocalization with FLAP were not disrupted with J147 but incubation with CNB-001 did display a
decrease colocalization of 5-LOX and FLAP at the nuclear membrane (Figure. 35) as depicted in
DMSO

CMB-001

J147

Figure 36. ImageJ Colocalization Analysis of 5-LOX and FLAP.
Colocalization scatter plots (from left to right) incubations with
vehicle(DMSO), CNB-001 and J147.
figure 36. The colocalization scatter plots display Mander’s coefficient and Pearson’s correlation
of the green and red fluorescence representative of 5-LOX and FLAP, respectively (Figure. 36)
Channel 1 represents red (FLAP) and channel 2 represents green (5-LOX). The DMSO control and
J147 incubations display the colocalization of green and red presented as yellow while the CNB001 incubation displays a dispersed green fluorescence that lays outside the vicinity of the red
fluorescence.
Impairment of Colocalization between 5-LOX and FLAP
While unstimulated HEK cells expressing 5-LOX are inhibited by J147, J147 does not fully inhibit
the cells when stimulated with calcium ionophore A23187. This may suggest that at 50 µM the
concentration of J147 is not high enough to fully inhibit the enzyme. However, 50 µM of CNB-001
fully inhibits 5-LOX product formation in both stimulated and unstimulated cells. How this relates
to the fact that CNB-001 may interfere with 5-LOX-FLAP colocalization is not clear at this point. IF
analysis displayed a sustained colocalization between 5-LOX and FLAP when HEK cells were
incubated with J147 while HEK cells incubated with CNB-001 displayed a reduced colocalization
between the two proteins.
Previous studies have demonstrated J147 to be a more potent suppressor of AD(132) than CNB001, however CNB-001 appears to be a more effective inhibitor of 5-LOX than J147. This could
suggest that J147 has other roles in suppressing AD besides inhibiting 5-LOX that have made it a
more effective candidate for treatment of AD. Both J147 and CNB-001 have been shown to be
effective drug candidates for treatment of AD. It is clear that 5-LOX may have a significant part in
the progression of AD, however more information needs to be obtained on the exact function of 5LOX and thus LT biosynthesis in the initiation and/or progression of AD and the mechanism of
action in which J147 and CNB-001 function to decrease the accumulation of amyloid proteins, and
therefore significantly reduce symptoms of AD.
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VI. Material and Methods
5-LOX Purification: His-tagged WT-5-LOX was expressed in Rosetta cells with a pET14B vector.
Bacteria were cultured at 37°C and 220 rpm for 4 hours and then at 20°C for an additional 27
hours. Cells expressing WT-5-LOX were lysed by sonication and the lysate was clarified by
centrifugation at 36,000 x g for 30 minutes. To the supernatant was added ammonium sulfate to
50% saturation. The precipitant was pelleted and resuspended in 100 mM Tris, 100 mM NaCl, 5
mM Imidazole, 2 mM tris(2-carboxyethyl)phosphine (TCEP), 10 μM FeSO4, 10 μg/ml catalase. The
resuspended precipitant was applied to a Co2+-affinity column. The column was washed with 100
mM Tris, 100 mM NaCl, 2 mM TCEP, 10 μM FeSO4, 20 mM imidazole and the immobilized enzyme
eluted with 100 mM Tris, 100 mM NaCl, 2 mM TCEP, 10 μM FeSO4, 10 μg/ml catalase, 200 mM
imidazole. After concentration of the eluant, protein concentration was determined with a
Nanodrop spectrophotometer. Protein purity was confirmed by SDS-PAGE. Purified protein was
frozen dropwise and stored in liquid N2.
5-LOX-TKM Purification: Bacterial cell cultures prepared as above were lysed by French press.
After clarification of the lysate by centrifugation at 36,000 x g, the supernatant was applied to a
Co2+-affinity column. The column was washed with 100 mM Tris, 500 mM NaCl, 20 mM imidazole.
The immobilized enzyme was eluted with 100 mM Tris, 500 mM NaCl, 200 mM imidazole. After
concentration of the eluant, protein concentration was determined with a Nanodrop
spectrophotometer. Protein purity was confirmed by SDS-PAGE. Purified protein was frozen
dropwise and stored in liquid N2.
Expression of 5-LOX and FLAP in HEK293 cells: HEK293 cells were transfected with WT-5-LOX,
TKM-5-LOX, and FLAP using the pcDNA3.1 vector for stable protein expression as described by
Gerstmeier et al (32). Cells were cultured at 37°C, 5% CO2 in Dubelco’s Modified Eagle Medium
(DMEM) with 10% fetal bovine serum (FBS, Atlanta Biologicals), in the presence of selection
antibiotic (G418 for 5-LOX; and hygromycin for FLAP (both from Sigma)). Successful protein
expression was confirmed by Western blotting.
Proteolytic Cleavage: Purified enzyme. Purified WT- and TKM-5-LOX were diluted to 9.8 μM in 100
mM Tris, 100 mM NaCl. The purified protein solutions were incubated with or without 2.5 μM
CaCl2 for 5 minutes. The solutions were then incubated with or without 5 μM chymotrypsin (2:1
protein to protease ratio) for 1 minute on ice. Samples were run on an SDS-PAGE gel and
transferred to a PVDF membrane with a Bio-Rad Trans-Blot system for Western development. The
primary antibodies were rabbit anti-5-LOX “Body” (amino acids 130-149) and rabbit anti-5-LOX
“Tail” (12 amino acids from the C-terminus). The secondary antibody utilized was goat anti-rabbit
AlexFlour647. Western blots were imaged with a Typhoon 9410 imager using channel 670 30 BP.
Cell lysates. HEK293 cells expressing WT- or TKM-5-LOX were collected and resuspended at 1 x
106 cells/ml in phosphate-buffered saline (PBS) plus 0.1% glucose. Cells were incubated with or
without 2.5 μM Ca2+-ionophore A23187 for 5 minutes in a 37°C water bath. The cells were spun
down and resuspended in lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA, 2% TritonX100),) before being incubated with 100 nM chymotrypsin for 1 minute on ice. Sample protein
concentrations were determined with a BCA protein assay kit (Pierce). Equivalent amounts of
protein were loaded onto 10% SDS-PAGE gels. After blotting onto PVDF membranes. The
resulting Western blots were developed as described above.
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Proteolytic Cleavage in Presence of AKBA: Purified enzyme. Purified WT-5-LOX was diluted to 9.8
μM in 100 mM Tris, 100 mM NaCl. The purified protein solutions were incubated with or without
2.5 μM CaCl2 for 5 minutes followed by incubation with AKBA at 0, 25, 50, 75 and 100 μM
concentrations for 10 minutes. The solutions were then treated as described above.
Cell lysates. HEK293 cells expressing WT-5-LOX with or without FLAP were collected and
resuspended at 1 x 106 cells/ml in phosphate-buffered saline (PBS) plus 0.1% glucose. Cells were
incubated with or without 2.5 μM Ca2+-ionophore A23187 for 5 minutes in a 37°C water bath
followed by a 10 minute incubation with AKBA at 0, 25, 50, 75 and 100 μM concentrations. Then the
cells were treated as described above.
5-LOX HPLC Product Analysis of HEK293 cells: HEK293 cells expressing WT- or TKM-5-LOX with
or without FLAP were collected and resuspended at 1 x 106 cells/ml PBS plus 0.1% glucose. Each
sample was incubated with or without 2.5 μM Ca2+-ionophore A23187 for 5 minutes at 37°C then
incubated for 10 minutes with 3 μM AA (Cayman). The reaction was stopped with the addition of 1
ml (1 volume) of methanol. Prior to solid phase extraction with C18 cartridges (UCT CLEAN-UP
C18 CEC1811Z), 0.5 ml PBS, 30 µl of 1 M HCl, and 10 µl of 50 ng/µl prostaglandin B1 (Cayman,
PGB1) were added. The products were eluted with methanol. The methanol was evaporated off
under N2 gas and the residue was resuspended in 60% acetonitrile, 0.1% formic acid, the HPLC
mobile phase. Samples were treated with triphenylphosphine as a reducing agent prior to HPLC
analysis. Isocratic reverse-phase HPLC was performed with a Supelco Discovery HSC18 column
monitored at 235 and 270 nm. Peaks for 5-HETE (235nm), leukotrienes and PGB1 (270 nm) were
integrated. Product levels were calculated relative to the peak area of the internal standard PGB1.
Activity analysis for HEK cells expressing TKM-5-LOX and FLAP with only endogenous AA pools
was performed in the same fashion above except without added AA and 5 incubations were
pooled for solid phase extraction of products.
5-LOX Product Analysis by HPLC in the Presence of AKBA: Purified enzyme. Purified WT-5-LOX
was diluted to 9.8 μM in 100 mM Tris, 100 mM NaCl. The purified protein solutions were incubated
with or without 2.5 μM CaCl2 for 5 minutes followed by incubation with AKBA at 0, 25, 50, 75 and
100 μM concentrations for 10 minutes. The solutions were then treated as described above.
Cell Lysates. HEK293 cells expressing WT-5-LOX with or without FLAP were collected and
resuspended at 1 x 106 cells/ml PBS plus 0.1% glucose. Each sample was incubated with 2.5 μM
Ca2+-ionophore A23187 for 5 minutes at 37°C followed by incubation with AKBA at 0, 25, 50, 75,
and 100 μM concentrations before being treated as described above.
15-LOX-2 Product Analysis in the presence of AKBA: HEK293 cells expressing WT-15-LOX-2 were
collected and resuspended at 1 x 106 cells/ml PBS plus 0.1% glucose. Each sample was incubated
with 2.5 μM Ca2+-ionophore A23187 for 5 minutes at 37°C, followed by incubation with AKBA at 0,
25, 50, 75, and 100 μM concentrations before being treated as described above.
5-LOX Product Analysis in HEK293 Cells in the Presence of J147 and CNB-001: HEK293 cells
expressing WT-5-LOX were collected and resuspended at 1 x 106 cells/ml PBS plus 0.1% glucose.
Each sample was incubated with 2.5 μM Ca2+-ionophore A23187 for 5 minutes at 37°C, followed
by incubation with J147 or CNB-001 at 50 μM concentration before being treated as described
above.
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Immunofluorescence Imaging of 5-LOX and FLAP in HEK293 Cells: HEK293 cells expressing WTor TKM-5-LOX with or without FLAP were seeded out at 200 cells/ml in each well of an Ibdi 12well slide. After 24-48 hours at 37°C 5% CO2, 2.5 μM Ca2+-ionophore A23187 was added to
stimulate the cells, which were then incubated for 5 minutes at 37°C 5% CO2. The cells were fixed
with 4% paraformaldye then washed 3 times with PBS. The cells were then incubated with a 50
mM NH4Cl solution, followed by a wash cycle and subsequently blocked for an hour with 10%
donkey serum, 0.1% Tween-20 in PBS. The samples were then incubated overnight at 4°C with a
primary antibody solution consisting of either rabbit anti-5-LOX “Body” +/- goat anti-FLAP or
rabbit anti-5-LOX “Tail” +/- goat anti-FLAP in 0.1% Tween-20 PBS solution. After a wash cycle with
0.1% Tween-20 PBS the cells were incubated with a secondary antibody solution consisting of
donkey anti-rabbit AlexaFluor488 +/- donkey anti-goat AlexaFluor647 in a 0.1% Tween-20 PBS
solution for 20 minutes. After another wash cycle, the cells were incubated with 2 μg/μl DAPI
solution for 3 minutes followed by another wash cycle. Invitrogen Prolong Gold antifade reagent
and a coverslip were then added to the slide. The slide was imaged with a Leica DM6B upright
microscope using DAPI, GFP (5-LOX), and Cy5 (FLAP) filters.
Immunofluorescence Imaging of 5-LOX and FLAP in HEK293 Cells in the Presence of AKBA:
HEK293 cells expressing WT-5-LOX with or without FLAP were seeded out at 200 cells/ml in each
well of an Ibdi 12-well slide. After 24-48 hours at 37°C 5% CO2, 2.5 μM Ca2+-ionophore A23187
was added to stimulate the cells, which were then incubated for 5 minutes at 37°C 5% CO2. AKBA
was then incubated at 0, 25, 50, 75, and 100 μM concentrations for 10 minutes at 37°C 5% CO2.
Then cells were prepared for immuno fluorescence imaging as stated above.
Immunofluorescence Imaging of 5-LOX and FLAP in HEK293 Cells in the Presence of J147 and
CNB-001: HEK293 cells expressing WT-5-LOX with or without FLAP were seeded out at 200
cells/ml in each well of an Ibdi 12-well slide. After 24-48 hours at 37°C 5% CO2, 2.5 μM Ca2+ionophore A23187 was added to stimulate the cells, which were then incubated for 5 minutes at
37°C 5% CO2. J147 or CNB-001 were then incubated at 50μM concentrations for 10 minutes at
37°C 5% CO2. Then cells were treated as stated above.
HEK Cell Protein Time-course in the Absence of Protein Synthesis: HEK cells expressing WT- or
TKM-5-LOX with or without FLAP were collected and resuspended at 1 x 106 cells/ml PBS plus
0.1% glucose. The cells were incubated with or without 2.5 μM Ca2+-ionophore A23187 for 5
minutes and then treated with 200 μM cycloheximide at 37°C and analyzed over eight time points
(0, 60, 90, 120, 150, 180, 210, and 240 min). An extra 200 μM cycloheximide was added after 120
minutes to ensure continuous inhibition of protein synthesis. At each time point 2 x 106 cells were
treated with lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA, 2% Triton-X100, 1 μM
pepstatin, leupeptin and PMSF). Sample protein concentrations were determined with a BCA
assay and equal amounts of protein were loaded onto 10% SDS-PAGE gels. The samples were
then analyzed by Western blot using rabbit anti-5-LOX “Tail” and goat anti-GAPDH primary
antibodies and donkey anti-rabbit AlexaFluor488 and donkey anti-goat AlexaFluor647 secondary
antibodies. Western blots were imaged with a Typhoon 9410 imager using channels 526 SP and
670 30 BP. For quantitative analysis of western bands we used ImageJ software.
qPCR HEK 5-LOX mRNA Quantification: RNA Isolation. Samples of 1 x 107 cells were collected for
each of the four cell lines, i.e., WT- or TKM-5-LOX with and without FLAP. After spinning down
cells and removing the media, the cells were resuspened in Trizol Reagent and incubated for 5
minutes at room temperature. Then, a 50/50 mixture of chloroform and isoamyl alcohol was mixed
with the samples and allowed to incubate for 3 minutes at room temperature. After centrifugation,
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the upper aqueous phase of the samples was transferred to a fresh tube. Isopropanol was mixed
with aqueous phase and incubated for 10 minutes at room temperature. The samples were again
centrifuged and the RNA pellet was washed twice with 75% ethanol and then let to air dry. The
RNA pellets were then dissolved in diethylpyrocarbonate (DEPC)-treated water before
undergoing DNase treatment where the samples were incubated with DNase I at 37°C for 30 min
then with the addition of 10 mM EDTA incubated at 70°C for 10 min. Next, the samples were
incubated with 300 mM sodium acetate and 2.5 volumes of ethanol at -80°C for 15 min before
being centrifugation at 4°C for 10 min. The RNA pellets were dissolved in DEPC-treated water and
concentration readings were taken by Nanodrop.
cDNA Synthesis and Gel Analysis: The isolated RNA (10 μg) served as a template for cDNA
synthesis using the Genescript reverse transcriptase kit (Promega). Forward and reverse oligos
for 5-LOXs and the GAPDH control were made by Integrated DNA Technologies (IDT) (Fig. S5).
Samples were then treated with RNaseH before undergoing PCR. The PCR samples were run on
an Agarose gel and analyzed visually. For quantitative analysis we used ImageJ software.
FLAP Purification: His-tagged FLAP was expressed in C43 (DE3) cells using the pET21b vector.
The cells were cultured at 37°C, 200rpm for 4 hours, induced with IPTG, and incubated an
additional 24 hours at 15°C. After cell lysis by sonication, the cell debris was cleared and 0.1%
dodecylmaltoside (DDM) was added and the sample was extracted at 4 °C overnight. The lysate
was subsequently applied to a Co2+-affinity column. The column was washed with 20mM Tris, 300
mM KCl, 50mM Imidazole, 20% glycerol and 0.1%DDM and the immobilized protein eluted with
20mM Tris, 300mM KCl, 250mM Imidazole, 20% glycerol and 0.1%DDM. After concentration of
eluant, protein concentration was determined with a Nanodrop spectrophotometer. Protein purity
was confirmed by SDS-PAGE. Purified protein was frozen dropwise and stored in liquid N2.
Membrane Scaffolding Protein (MSP) Purification: His-tagged MSP1E3D1 was expressed in
Rosetta 2 (DE3) cells using the pET28 vector. Cells were cultured at 37.5°C 250 rpm for 4-6 hours.
Cells were induced with 500 mM IPTG and let to culture for an hour at 37.5°C before lowering the
temperature to 28°C for an additional 3 hours. After lysing cells by sonication and clarifying the
lysate, the lysate was applied to a Co2+-affinity column. The column was washed with four
different buffers each containing 40mM Tris-HCl 300mM NaCl at pH 8.0: Buffer 1 (+1% Triton),
Buffer 2 (+50mM cholate), Buffer 3 (no addition), Buffer 4 (+20mM Imidazole). The protein was
eluted with 40mM Tris-HCl 300mM NaCl 300mM Imidazole. After concentrating, the protein A280
was read on a Nanodrop. Protein was frozen in liquid N2 and stored at -80°C.
Empty-Nanodisc Construction: A phospholipid mixture of 75% (POPC), 25% (POPS), and 2%
(SAPC) was suspended in 20mM Tris, 150 mM NaCl, 0.5 mM EDTA and 100 mM cholate. Purified
MSP was added to a phospholipid mixture at a 140:2 PL:MSP ratio. Additional cholate was added
as necessary to maintain the cholate concentration at 25 mM or more. The mixture with a total
volume of 100μl was incubated for one hour on a nutator at 4°C. Then ~5 Bio-Beads were added to
mixture and rotated overnight at 4°C. The solution was then run through Bio-Beads to adsorb all
the remaining cholate. The Nanodiscs were purified by Co2+ affinity chromatography. After
concentration, the A280 was read on a Nanodrop. The nanodisc solution was then stored at 4°C.
FLAP-Nanodisc Construction: A phospholipid mixture of 75% (POPC), 25% (POPS), and 2%
(SAPC) was suspended in 20mM Tris, 150mM NaCl, 0.5mM EDTA and 100mM cholate. Purified
MSP was treated with tobacco etch virus (TEV) protease to remove Histidine tag and termed
clipped MSP (cMSP). Purified cMSP and FLAP were added to phospholipid mixture at a 140:2:2
PL:MSP:FLAP ratio. Additional cholate was added as necessary to maintain the cholate
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concentration at 25mM or more. The mixture with a total volume of 200μl was incubated for one
hour on a nutator at 4°C. Then ~5 Bio-Beads were added to mixture and rotated overnight at 4°C.
The solution was then run through Bio-Beads to adsorb all the remaining cholate. The FLAP-ND
were purified by Histidine affinity chromatography. After concentration, the A280 was read on a
Nanodrop. The nanodisc solution was then stored at 4°C.
5-LOX-FLAP/EMPTY-Nanodisc Assembly: 5-LOX with either Empty or FLAP nanodiscs were
incubated together at a 1:1 ratio for 30min at 4°C. The 5-LOX-FLAP/Empty-ND complex was
purified by size exclusion chromatography (SEC) with a running buffer of 20mM Tris 150mM NaCl
and 0.5mM EDTA. The peak fractions were concentrated with 30K Amicon filters and run on a gel
which were stained with Sypro Ruby as well as analyzed by Western blot for detection of both 5LOX and FLAP.
Negative Stain Transmission Electron Microscopy (TEM) Imaging: A 300 square mesh copper grid
was glow discharged for 30 seconds before 4µl of sample of either Empty-NDs, FLAP-NDs, 5-LOXEmpty-NDs or 5-LOX-FLAP-NDs was applied for 1 minute. After blotting with filter paper, the grid
was incubated on a drop of 2% uranyl acetate for 3min, then blotted and left to dry. Imaging was
done on a JEOL 1400 TEM operating with LaB6 filament at 120kV. Images were captured with a 2K
x2K CCD camera.
Cryo-TEM Imaging of Empty-Nanodiscs: Quantifoil R2/4 400 mesh copper holey grids were glow
discharged for 30 seconds before 5µl of Empty-ND sample was applied. Using a Gatan Cryo
Plunge, grids were mechanically blotted on both sides for 2 seconds before being plunged in to
liquid ethane and vitrified. The sample was imaged on the instrument stated above with the
minimal dose system (MDS) and kept under cryo conditions with a Gatan cryo-holder.
Immuno-gold and Negative Stain TEM Imaging: Either FLAP-NDs or 5-LOX-FLAP-NDs were
applied to glow discharged 300 square mesh copper grids for 3min. After blotting with filter
paper, the grid was placed on a drop of 4% PFA for 10min. Then the grid went through a 3 drop
wash cycle at 5min/drop with PBS, a 50mM NH4Cl incubation for 10min, and lastly another wash
cycle. Following a blocking solution incubation of 1hr, the grid was then incubated in either
rabbit anti-5-LOX or goat anti-FLAP primary antibody solution for 1hr. After a wash cycle, the grid
was incubated for an additional hour in either donkey anti-rabbit or donkey anti-goat 10nm
immuno-gold secondary antibody solution, followed by a wash cycle. The grid was then stained
with 2% uranyl acetate for 2min, blotted and let to dry. Images were taken on a JEOL 1400 at
120kV.
Native Gel Analysis of 5-LOXWT-FLAP-Nanodisc Complex: Purified WT-5-LOX, FLAP, Empty-NDs,
FLAP-NDs, 5-LOX-Empty-NDs, and 5-LOX-FLAP-NDs were run on a clear native gel. 5-LOX and
FLAP-ND were incubated at either a 0.25:1, 0.5:1, 1:1, or 2:1 5-LOX:FLAP-ND ratio with 100nM
CaCl2 for 5 minutes on a nutator at 4°C. Each sample was loaded and run on a native gel at 4°C for
4-5 hours. Gels were fixed with 50% methanol 7% acetic acid solution before being stained with
Sypro ruby overnight. Western blot of gel was developed with a goat anti-FLAP primary antibody
and a donkey anti-goat AlexFluor 647 secondary antibody. Gels and westerns were imaged with
Typhoon 9410 imager using channel 610 and channel 670 30 BP, respectively.
Native Gel Analysis of 5-LOXWT-FLAP-Nanodisc Complex in Presence of AKBA: Purified WT-5LOX and FLAP-Nanodiscs were incubated at a 1:1 ratio for 5 minutes before being incubated with
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AKBA at 0,25,50,75, and 100 μM concentrations for 10 minutes on the nutator at 4°C. Native gel
was run as stated above.
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Conclusion
Although there has been a significant amount of research done on the leukotriene biosynthesis
pathway, more information is needed to fully understand its regulation and the balance of this
pathway with other arachidonic acid derived lipid mediator pathways. My research has
contributed insight into the regulation of 5-LOX and FLAP as the initiators of LT biosynthesis.
Analyzing the unique triple lysine motif (KKK653-655) in 5-LOX gave us information into why 5-LOX
would require the helper protein, FLAP. My data suggests that this motif acts as a modulator of 5LOX activity for the effective balance of LT biosynthesis. Product analysis done with HEK293 cells
demonstrated that WT-5-LOX stimulated to the nuclear membrane in the absence of FLAP
displayed a weak production of 5-HETE and LTs. However, if this motif is mutated to a more stable
sequence (ENL) a significant ~20-fold increase in product formation was observed. Moreover,
when either wildtype or the mutant was expressed with FLAP, product formation increased 3-fold
for WT-5-LOX but the mutant activity was reduced to wildtype levels. This data displays a
Goldilocks story where 5-LOX with the KKK motif produces too little LTs for an effective
inflammatory response and the ENL substitution of this motif produces too much, therefore
causing a detrimental response. The WT-enzyme with FLAP produces just the right amount of
products for effective LT biosynthesis. Moreover, the elevated activity of the mutant enzyme was
abolished when product analysis was examined in cell homogenates, where the cell membranes
are broken. Therefore not only does FLAP play an important regulatory role in LT biosynthesis,
but the 5-LOX triple lysine motif may require the membrane for its role in modulating 5-LOX
activity. This data along with the observation of turn-over dependent inactivation through cellular
protein sustainability analysis demonstrates this motif to be an intricate and finely-tuned control
mechanism to regulate LT biosynthesis in conjunction with FLAP. The next step in analyzing the
triple lysine motif is addressing the role of the nuclear membrane in the function of this motif to
better understand exactly how the KKK motif modulates 5-LOX activity.
The observation of allosteric inhibition of 5-LOX by the natural product AKBA and its effect on the
5-LOX-FLAP interaction has provided new insights into a unique inhibitor development. The x-ray
crystal structure of Stable-5-LOX with AKBA bound solved by Dr. Nathanial Gilbert defined an
allosteric binding site for AKBA between 5-LOX’s membrane binding domain and its catalytic
domain. Product analysis of 5-LOX in HEK293 cells in the presence of AKBA demonstrated a
change in product specificity by 5-LOX-only expressing cells. The 5-LOX expressing cells
produced 12-HETE over 5-HETE with increasing concentrations of AKBA. However, with cells
expressing both 5-LOX and FLAP, LT formation was diminished and 5-HETE cut in half at 25µM
AKBA incubations. All product production was lost in incubations with higher concentrations of
AKBA. Immuno-fluorescence microscopy of 5-LOX and FLAP in HEK cells displayed a decrease in
colocalization of the two proteins at the nuclear membrane. This data suggests that AKBA may
disrupt the interaction between 5-LOX and FLAP, therefore preventing 5-LOX’s access to
substrate from FLAP. Native gel analysis of an in vitro 5-LOX-FLAP-ND complex supports this
further by demonstrating a decreased association between 5-LOX and FLAP-ND in the presence
of AKBA. This data demonstrates that the binding of AKBA to 5-LOX may induce a small
conformational change in 5-LOX that changes the product specificity of the active site as well as
prevents substrate acquisition from FLAP. This allosteric inhibition may display the ability of
AKBA to inhibit pro-inflammatory responses (LTs) while promoting anti-inflammatory responses
(5-HPETE/12-HPETE).
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The next steps in analyzing this inhibitor as an effective anti-inflammatory compound is to address
how AKBA effects the balance of pro and anti-inflammatory LOX mediated pathways, as well as
creating a mimic of AKBA that could effectively be transported into cells.
Reconstructing the 5-LOX-FLAP interaction in vitro with the use of nanodiscs allowed us the
opportunity to analyze the structural and functional relationship between 5-LOX and FLAP.
Previous studies have strongly suggested an interaction between 5-LOX and FLAP, but it has
never been proven. Moreover, an interaction between solubilized 5-LOX and detergent
solubilized FLAP has never been observed in vitro. The membrane appears to play a significant
role in the 5-LOX-FLAP interaction. The incorporation of FLAP into nanodiscs allowed for a
favorable interaction between 5-LOX and FLAP-NDs. Nanodiscs were constructed with lipids that
mimicked the lipid make-up of nuclear membrane. Empty-NDs, FLAP-NDs, 5-LOX-Empty-NDs,
and 5-LOX-FLAP-NDs were analyzed by single-particle TEM. TEM imaging of FLAP-NDs revealed
FLAP as a dark spot inside the center of the ND structure and FLAP was confirmed to be
incorporated by immuno-gold labeling of FLAP. TEM imaging of 5-LOX-FLAP-NDs revealed a side
view of the complex which displayed two copies of 5-LOX sitting on top a FLAP-ND. Although
optimization of complex imaging is needed, current micrographs of the 5-LOX-FLAP-ND complex
can be seen coming together. The 5-LOX enzymes demonstrated in the micrograph were
measured at 8.9nm which is comparable to the shape and length of the 5-LOX crystal structure.
This observation is strengthened by the fact that when 5-LOX-Empty-NDs are imaged by TEM this
association between 5-LOX and the nanodiscs is not observed. Therefore, the clustering of 5-LOX
and FLAP-NDs is due to the attraction between 5-LOX and FLAP. Furthermore, clear native gel and
western blot analysis demonstrated an affinity of 5-LOX for FLAP-NDs by a display of a significant
migration change by FLAP-NDs when in the presence of 5-LOX. Preliminary HPLC product
analysis of 5-LOX-Empty-NDs and 5-LOX-FLAP-NDs demonstrated substrate acquisition by 5-LOX
from either the bilayer of Empty-NDs or FLAP. Although only the intermediate 5-LOX product was
detected, further analysis by LC/MS/MS is being done to detect LT products. The next step in
studying the 5-LOX-FLAP-NDs interaction is single-particle cryo-EM imaging of the complex and
obtaining data sufficient for three-dimensional reconstruction of the 5-LOX-FLAP-ND structure.
The overall complex structure with the known individual protein x-ray crystal structures docked
inside could provide insight into the domains of 5-LOX that interact with FLAP and/or the
membrane. This information would offer a better understanding of the mechanism of the initiation
of LT biosynthesis.
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Appendix B: Supplemental Figures for Chapter III

Supplemental Figure 1. The
transformation of AA to LTA4.
Oxygenation of arachidonic acid
(top) produces 5-HPETE (middle)
which is further transformed to
LTA4 (bottom).
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Supplemental Figure 2. Colocalization of 5-LOX and FLAP in HEK 293 cells.
Immuno-fluorescence labeling of WT-5-LOX FLAP and TKM-5-LOX FLAP in
HEK cells. Colocalization of 5-LOX and FLAP analyzed by ImageJ in
development with both “Tail” and “Body” primary antibodies. A. WT-5-LOX
FLAP anti-5-LOX “Body” B. WT-5-LOX FLAP anti-5-LOX “Tail” C. TKM-5-LOX
FLAP anti-5-LOX “Body” D. TKM-5-LOX FLAP anti-5-LOX “Tail”. All Pearson’s
Correlation (Rr) and Mander’s Overlap Correlation (R) numbers represented
successful colocalization.
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Supplemental Figure 3. qPCR of 5-LOX
mRNA from HEK 293 cells. Top, ImageJ
band intensity analysis of 5-LOX cDNA
relative to GAPDH cDNA in HEK cells.
Bottom, Agarose gel of 5- LOX and
GAPDH DNA bands. From left to right,
HEK 293 untransfected, WT-5-LOX,
TKM-5-LOX, WT-5-LOX FLAP and TKM5-LOX FLAP. Transcript levels do not
vary significantly among the samples.
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Supplemental Figure 4. TKM-5-LOX FLAP
expressing cells show LT formation without the
addition of exogenous AA. A. Spectrum
consistent with LTA4 hydrolysis products
generated in HEK cells expressing TKM-5-LOX
and FLAP. B. Overall product levels of TKM-5LOX FLAP cells stimulated with Ca2+-ionophore
A21387.
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Supplemental Figure 5. mRNA sequence targets for 5-LOX
and GAPDH. A. 5-LOX, 336bp. B. GAPDH, 330bp. Primers are
indicated in yellow.
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